

	ADRENACARD Trademark of Intelliject, Inc.. Serial Number: 78604789 :: Trademarkia Trademarks





























































Apply Online!
Attorneys

Services 

U.S. Trademark Registration Service 
International Trademark Registration Service 
Trademark Office Action Response 
Trademark Statement of Use 
Trademark Renewal 
Trademark Assignment 
Trademark Watch 
Trademark Cease & Desist  
Trademark Comprehensive Search  
Copyright Registration 
Patent Services 
Incorporation Services 
Business Page Creation 
 More Services... 


Help
Contact Us


Login






















Trademark Search 
Trademark Category
Medical Instrument Products
ADRENACARD










 
Get FREE email alerts













ADRENACARD  Trademark Information
 Intelliject, Inc.
Human Hypodermic Injectors




Perfect for these industries

Medical Instrument Products





Words that describe this mark
human   hypodermic   injectors    
                                    




This is a brand page for the ADRENACARD trademark by Intelliject, Inc. 
                                in RICHMOND, VA, 23219.
Write a review about a product or service associated with this ADRENACARD trademark.    
                                Or, contact the owner Intelliject, Inc. of the ADRENACARD trademark by filing a request to communicate with    
                                the Legal Correspondent for licensing, use, and/or questions related to the ADRENACARD trademark.
                           






On Friday, April 8, 2005,  a U.S. federal trademark registration was filed for 
                        ADRENACARD by 
                        Intelliject, Inc., RICHMOND, VA  23219.
                        The USPTO has given the ADRENACARD 
                        trademark serial  number of  78604789.  
                        The current federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED.
                        The correspondent listed for ADRENACARD is 
                        
                        
                                            Peter J. Willsey of 
                                            COOLEY LLP,  1299 Pennsylvania Avenue NW, Suite 700, WASHINGTON DC 20004 
                                .
                            The ADRENACARD trademark is filed in the category of 
                            
                                    Medical Instrument Products
                                . 
                            The description provided to the USPTO for ADRENACARD 
                            is Human Hypodermic Injectors. 
                            





Word mark:
 ADRENACARD


  Status/Status Date:  


ABANDONED - NO STATEMENT OF USE FILED

5/11/2009






  Serial Number:  
78604789


  Filing Date:  
4/8/2005


 Registration Number:  
NOT AVAILABLE


 Registration Date:  
NOT AVAILABLE


 Goods and Services: 
Human Hypodermic Injectors


 Mark Description: 
NOT AVAILABLE


 Type Of Mark: 
TradeMark


 Published For Opposition Date: 
1/17/2006


Last Applicant/Owner:

Intelliject, Inc.RICHMOND, VA  23219
Why is this contact information displayed?  

Why is this contact information displayed? [Close]
The USPTO makes this data available for search by the public so that individuals can locate ownership information for intellectual property, much the same way a county might make real estate property ownership information available.
Since our website is synchronized with the USPTO data, we recommend making any data changes with the USPTO directly. Our website will auto-update when the USPTO data is updated.
You may also contact Trademarkia to make a request for the removal of your personally identifiable information or trademark data.  Such requests must be made in writing and will be subject to verification of ownership.  This policy allows verified trademark owners to specify: (A) that their identifiable information be masked, or (B) that their trademark pages permanently deleted from Trademarkia.com.  
                                                Requests may be made directly to customer.service@trademarkia.com and every effort will be made to honor them within 48 hours. 
Click here for further details.
[Close]




 Mark Drawing Code:  
Standard Character Mark


 Design Search: 


(NO DATA)



Register Type:  
Principal


 Disclaimer:
 (NOT AVAILABLE)


 Correspondent:


Peter J. Willsey
COOLEY LLP
1299 Pennsylvania Avenue NW, Suite 700
WASHINGTON DC 20004






 Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.





Classification Information



Primary Class: 
 Class (010) - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.


First Use Anywhere: 
Not provided


First Use In Commerce: 
Not provided





Trademarkia is the largest search engine for U.S. trademarks.  Each month hundreds of trademarks around the world are filed by licensed attorneys in the LegalForce/Trademarkia network! You can register your trademark in 170+ countries in the world through LegalForce Network.
 LegalForce Network can help you incorporate a business around your ADRENACARD trademark in less than 5 minutes.  Trademarkia makes the process easy and convenient, so start now!
 Trademarkia.com is a free search engine of publicly available government records.  Trademarkia.com is not a law firm and does not represent owners & correspondents listed on this page.
Trademark Document Retrieval >>







Trademark - Apply Online!


100% Satisfaction Guarantee protect your valuable brand now.



How it works?
What you get?






1. Legalforce RAPC - #1 U.S. Trademark Filing from 2010 to now.
2. Describe how your business or product is being used. Register your mark in 176+ countries. Just $199 + govt fees! Start here >>






1. Top Global IP Attorneys - Credibility and Experience!
2. All processes will be performed in a timely manner. You will be informed periodically about the process.






Keep Track of this Brand.

 Trademark Watch Services
Keep track of how your trademark is being used. Available in the United States and in more than 176 countries. Round-the-clock monitoring. Monthly report on potential infringement.
                                

Watch this Trademark 

Trademark Watch Services read more...

Current Trademark Status:

5/11/2009
ABANDONED - NO STATEMENT OF USE FILED


Free Trademark Search:






Correspondent Search:



Peter J. Willsey


                                             
                                         is a correspondent of ADRENACARD trademark. 
                            	    


Current Overall Rating:

 (0 review)
                            
What You Can Do:




Start Your Business



FREE Logo Creator



Add to Favorites



View Documents



FREE Trademark Search



Start Trademark Filing Process



Protect this Mark Internationally



Custom Logo Design $159



Search adrenacard on popular social networks






                                Trademarkia lets you see how your 
                                personal name, product name, 
                                trademark name or username is being used on any of 530+ new 
                                and popular social networks.  
                                Be the first to reserve your name  and get help stopping others from using it - all in one place!















Trademark Oppose Service


You can request for Extension of Time to Oppose this mark or Oppose it now.



                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password;
                 

                 - If you already have a LegalForce/Trademarkia account, please enter your account's email and password.
                


* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



* 



 Please enter the value




 

  
                             



 







Status Update Alerts

Status Update Alerts are email updates of the latest trademark status change. Please make sure you provide the correct email. 


                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password;
                 

                 - If you already have a LegalForce/Trademarkia account, please enter your account's email and password.
                


* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



* 



 Please enter the value




 

  
                             



 









Review & Rating

Please Rate and Review for ADRENACARD 




ADRENACARD is providing Human Hypodermic Injectors.
                


                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password to be associated with your review.
                 

                 If you already have a LegalForce/Trademarkia account, please enter your account's email and password before posting your review.
                 


* Please Rate: 


     




* Your Review: 



 Please enter your review.



* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



 

  
                             



 




















Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version





















ADRENACARD Trademark Application of AdrenaCard, Inc. - Serial Number 86886773 :: Justia Trademarks































































Log In
Sign Up











Find a Lawyer
Ask a Lawyer 
Research the Law
Law Schools
Laws & Regs
Newsletters
Legal Marketing








ADRENACARD - Trademark DetailsStatus: 730 - First Extension - GrantedSerial Number86886773Word MarkADRENACARDStatus730 - First Extension - GrantedStatus Date2017-03-15Filing Date2016-01-26Mark Drawing4000 - Standard character mark 
TypesetPublished for Opposition Date2016-06-21Attorney NameErnest W. GrumblesLaw Office Assigned Location CodeM70Employee NameBRECKENFELD, WILLIAM GStatementsGoods and ServicesInjectors sold filled with hormones, antidotes, anti-epileptic pharmaceutical preparations and biologicsGoods and ServicesMedical apparatus, namely, an injection device for administering drugs and other medical fluids; drug delivery systemsClassification InformationInternational Class005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.US Class Codes006, 018, 044, 046, 051, 052Class Status Code6 - ActiveClass Status Date2016-01-30Primary Code005International Class010 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials. - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials.US Class Codes026, 039, 044Class Status Code6 - ActiveClass Status Date2016-01-30Primary Code010Current Trademark OwnersParty NameAdrenaCard, Inc.Party Type20 - Owner at PublicationLegal Entity Type03 - CorporationAddressPlease log in with your Justia account to see this address.Trademark Owner HistoryParty NameAdrenaCard, Inc.Party Type20 - Owner at PublicationLegal Entity Type03 - CorporationAddressPlease log in with your Justia account to see this address.Party NameAdrenaCard, Inc.Party Type10 - Original ApplicantLegal Entity Type03 - CorporationAddressPlease log in with your Justia account to see this address.CorrespondencesNameERNEST W. GRUMBLESAddressPlease log in with your Justia account to see this address.Trademark EventsEvent DateEvent Description2016-01-29NEW APPLICATION ENTERED IN TRAM2016-01-30NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2016-05-11ASSIGNED TO EXAMINER2016-05-13APPROVED FOR PUB - PRINCIPAL REGISTER2016-06-01NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2016-06-21PUBLISHED FOR OPPOSITION2016-06-21OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2016-08-16NOA E-MAILED - SOU REQUIRED FROM APPLICANT2017-02-24TEAS PETITION TO REVIVE RECEIVED2017-02-24PETITION TO REVIVE-GRANTED2017-02-24EXTENSION RECEIVED WITH TEAS PETITION2017-02-24NOTICE OF REVIVAL - E-MAILED2017-03-12CASE ASSIGNED TO INTENT TO USE PARALEGAL2017-02-16EXTENSION 1 FILED2017-03-15EXTENSION 1 GRANTED2017-03-16NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED





Today on Verdict



Unprotected: Lesbian Co-Parent in Idaho Has No Rights to Her Partner’s Biological Child



SMU Dedman School of Law professor Joanna L. Grossman comments on a recent decision by the Idaho Supreme Court taking a narrow view of the parental rights of lesbian co-parents.





Ask a Lawyer







Question:




Add details
120



Additional Details: 




					    	1000
					    


Ask Question






Find a Lawyer
















Lawyers - Get Listed Now!

Get a free directory profile listing







 



            Justia Legal Resources
        



Find a Lawyer





Bankruptcy Lawyers
Business Lawyers
Criminal Lawyers
Employment Lawyers
Estate Planning Lawyers
Family Lawyers
Personal Injury Lawyers
More... 




Individuals





Bankruptcy
Criminal
Divorce
DUI
Estate Planning
Family Law
Personal Injury
More...




Business





Business Formation
Business Operations
Employment
Intellectual Property
International Trade
Real Estate
Tax Law
More... 




Law Students





Law Schools
Admissions
Financial Aid
Course Outlines
Law Journals
Blogs
Employment
More...




US Federal Law





US Constitution
US Code
Regulations
Supreme Court
Circuit Courts
District Courts
Dockets & Filings
More...




US State Law





State Constitutions
State Codes
State Case Law
California
Florida
New York
Texas
More... 




Other Databases





Legal Blogs
Legal Forms
GAO Reports
Product Recalls
Patents
Trademarks
Countries
More...




Legal Marketing





Websites
Blogs
Content
Social Media
Local Marketing
Paid Ads (CPC/PPC)
Lawyer Directory
More...












 
                    © 2017 Justia



Company
Terms of Service
Privacy Policy
Help
Marketing Solutions












Trademark Categories by Justia :: Justia Trademarks































































Log In
Sign Up











Find a Lawyer
Ask a Lawyer 
Research the Law
Law Schools
Laws & Regs
Newsletters
Legal Marketing








Trademark CategoriesGoods
ChemicalsRead moreChemicals used in industry, science and photography, as well as in agriculture, horticulture and forestryUnprocessed artificial resins, unprocessed plasticsManuresFire extinguishing compositionsTempering and soldering preparationsChemical substances for preserving foodstuffsTanning substancesAdhesives used in industryClothingRead moreClothing, footwear, headgearCollective Membership MarkRead moreCollective Membership MarkCordage and fibersRead moreRopes, string, nets, tents, awnings, tarpaulins, sails, sacks and bags (not included in other classes)Padding and stuffing materials (except of rubber or plastics)Raw fibrous textile materialsCosmetics and cleaning preparationsRead moreBleaching preparations and other substances for laundry useCleaning, polishing, scouring and abrasive preparationsSoapsPerfumery, essential oils, cosmetics, hair lotionsDentifricesElectrical and scientific apparatusRead moreScientific, nautical, surveying, electric, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instrumentsApparatus for recording, transmission or reproduction of sound or imagesMagnetic data carriers, recording discsAutomatic vending machines and mechanisms for coin-operated apparatusCash registers, calculating machines, data processing equipment and computersFire-extinguishing apparatusEnvironmental control apparatusRead moreApparatus for lighting, heating, steam generating, cooking, refrigerating, drying, ventilating, water supply and sanitary purposesFabricsRead moreTextiles and textile goods, not included in other classesBed and table coversFancy goodsRead moreLace and embroidery, ribbons and braidButtons, hooks and eyes, pins and needlesArtificial flowersFirearmsRead moreFirearmsAmmunition and projectilesExplosivesFireworksFloor coveringsRead moreCarpets, rugs, mats and matting, linoleum and other materials for covering existing floorsWall hangings (non-textile)Furniture and articles not otherwise classifiedRead moreFurniture, mirrors, picture framesGoods (not included in other classes) of wood, cork, reed, cane, wicker, horn, bone, ivory, whalebone, shell, amber, mother-of-pearl, meerschaum and substitutes for all these materials, or of plasticsGoods Certification MarkRead moreGoods Certification MarkHand toolsRead moreHand tools and implements (hand-operated)CutlerySide armsRazorsHousewares and glassRead moreHousehold or kitchen utensils and containers (not of precious metal or coated therewith)Combs and spongesBrushes (except paint brushes)Brush-making materialsArticles for cleaning purposesSteelwoolUnworked or semi-worked glass (except glass used in building)Glassware, porcelain and earthenware not included in other classesJewelryRead morePrecious metals and their alloys and goods in precious metals or coated therewith, not included in other classesJewellery, precious stonesHorological and chronometric instrumentsLeather goodsRead moreLeather and imitations of leather, and goods made of these materials and not included in other classesAnimal skins, hidesTrunks and travelling bagsUmbrellas, parasols and walking sticksWhips, harness and saddleryLight beveragesRead moreBeersMineral and aerated waters and other non-alcoholic drinksFruit drinks and fruit juicesSyrups and other preparations for making beveragesLubricants and fuelsRead moreIndustrial oils and greasesLubricantsDust absorbing, wetting and binding compositionsFuels (including motor spirit) and illuminantsCandles, wicksMachineryRead moreMachines and machine toolsMotors and engines (except for land vehicles)Machine coupling and transmission components (except for land vehicles)Agricultural implements (other than hand-operated)Incubators for eggsMeats and processed foodsRead moreMeat, fish, poultry and gameMeat extractsPreserved, dried and cooked fruits and vegetablesJellies, jams, fruit saucesEggs, milk and milk productsEdible oils and fatsMedical apparatusRead moreSurgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teethOrthopedic articlesSuture materialsMetal goodsRead moreCommon metals and their alloysMetal building materialsTransportable buildings of metalMaterials of metal for railway tracksNon-electric cables and wires of common metalIronmongery, small items of metal hardwarePipes and tubes of metalSafesGoods of common metal not included in other classesOresMusical InstrumentsRead moreMusical instrumentsNatural agricultural productsRead moreAgricultural, horticultural and forestry products and grains not included in other classesLive animalsFresh fruits and vegetablesSeeds, natural plants and flowersFoodstuffs for animals, maltNonmetallic building materialsRead moreBuilding materials (non-metallic)Non-metallic rigid pipes for buildingAsphalt, pitch and bitumenNon-metallic transportable buildingsMonuments, not of metalPaintsRead morePaints, varnishes, lacquersPreservatives against rust and against deterioration of woodColorantsMordantsRaw natural resinsMetals in foil and powder form for painters, decorators, printers and artistsPaper goods and printed matterRead morePaper, cardboard and goods made from these materials, not included in other classesPrinted matterBookbinding materialPhotographsStationeryAdhesives for stationery or household purposesArtists' materialsPaint brushesTypewriters and office requisites (except furniture)Instructional and teaching material (except apparatus)Plastic materials for packaging (not included in other classes)Playing cardsPrinters' typePrinting blocksPharmaceuticalsRead morePharmaceutical, veterinary and sanitary preparationsDietetic substances adapted for medical use, food for babiesPlasters, materials for dressingsMaterial for stopping teeth, dental waxDisinfectantsPreparations for destroying verminFungicides, herbicidesRubber goodsRead moreRubber, gutta-percha, gum, asbestos, mica and goods made from these materials and not included in other classesPlastics in extruded form for use in manufacturePacking, stopping and insulating materialsFlexible pipes, not of metalSmokers’ articlesRead moreTobaccoSmokers' articlesMatchesStaple foodsRead moreCoffee, tea, cocoa, sugar, rice, tapioca, sago, artificial coffeeFlour and preparations made from cereals, bread, pastry and confectionery, icesHoney, treacleYeast, baking-powderSalt, mustardVinegar, sauces (condiments)SpicesIceToys and sporting goodsRead moreGames and playthingsGymnastic and sporting articles not included in other classesDecorations for Christmas treesVehiclesRead moreVehiclesApparatus for locomotion by land, air or waterWine and spiritsRead moreAlcoholic beverages (except beers)Yarns and threadsRead moreYarns and threads, for textile useServices
Advertising and businessRead moreAdvertisingBusiness managementBusiness administrationOffice functionsBuilding construction and repairRead moreBuilding constructionRepairInstallation servicesComputer and scientificRead moreScientific and technological services and research and design relating theretoIndustrial analysis and research servicesDesign and development of computer hardware and softwareLegal servicesEducation and entertainmentRead moreEducationProviding of trainingEntertainmentSporting and cultural activitiesHotels and restaurantsRead moreServices for providing food and drinkTemporary accommodationInsurance and financialRead moreInsuranceFinancial affairsMonetary affairsReal estate affairsMedical, beauty and agriculturalRead moreMedical servicesVeterinary servicesHygienic and beauty care for human beings or animalsAgriculture, horticulture and forestry servicesPersonalRead morePersonal and social services rendered by others to meet the needs of individualsSecurity services for the protection of property and individualsServices Certification MarkRead moreServices Certification MarkTelecommunicationsRead moreTelecommunicationsTransportation and storageRead moreTransportPackaging and storage of goodsTravel arrangementTreatment of materialsRead moreTreatment of materialsMemberships
Certification MarkCollective Membership MarkCollective Service MarkCollective TrademarkService MarkTrademark





Today on Verdict



Unprotected: Lesbian Co-Parent in Idaho Has No Rights to Her Partner’s Biological Child



SMU Dedman School of Law professor Joanna L. Grossman comments on a recent decision by the Idaho Supreme Court taking a narrow view of the parental rights of lesbian co-parents.





Ask a Lawyer







Question:




Add details
120



Additional Details: 




					    	1000
					    


Ask Question






Find a Lawyer
















Lawyers - Get Listed Now!

Get a free directory profile listing







 



            Justia Legal Resources
        



Find a Lawyer





Bankruptcy Lawyers
Business Lawyers
Criminal Lawyers
Employment Lawyers
Estate Planning Lawyers
Family Lawyers
Personal Injury Lawyers
More... 




Individuals





Bankruptcy
Criminal
Divorce
DUI
Estate Planning
Family Law
Personal Injury
More...




Business





Business Formation
Business Operations
Employment
Intellectual Property
International Trade
Real Estate
Tax Law
More... 




Law Students





Law Schools
Admissions
Financial Aid
Course Outlines
Law Journals
Blogs
Employment
More...




US Federal Law





US Constitution
US Code
Regulations
Supreme Court
Circuit Courts
District Courts
Dockets & Filings
More...




US State Law





State Constitutions
State Codes
State Case Law
California
Florida
New York
Texas
More... 




Other Databases





Legal Blogs
Legal Forms
GAO Reports
Product Recalls
Patents
Trademarks
Countries
More...




Legal Marketing





Websites
Blogs
Content
Social Media
Local Marketing
Paid Ads (CPC/PPC)
Lawyer Directory
More...












 
                    © 2017 Justia



Company
Terms of Service
Privacy Policy
Help
Marketing Solutions













Pharmaceuticals Trademarks :: Trademark Resources :: Justia Trademarks































































Log In
Sign Up











Find a Lawyer
Ask a Lawyer 
Research the Law
Law Schools
Laws & Regs
Newsletters
Legal Marketing








Pharmaceuticals Trademarks by Filing Date
2017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987198619851984198319821981198019791978197719761975197419731972197119701969196819671966196519641963196219611960195919581957195619551954195319521951195019491948194719461945194419431942194119401939193819371936193519341933193219311930192919281927192619251924192319221921192019191918191719161915191419131912191119101909190819071906190519041903190219011900189918981897189618951894189318921891189018871884Latest Pharmaceuticals Trademarks 






DISOLVATOL

Herbal supplementsOwned by: Kidney Stone Labs LLCSerial Number: 87534848











SPEDYON

Pharmaceutical preparations for the treatment of dermatological diseases and conditionsOwned by: Sol-Gen Technologies LtdSerial Number: 87535108











BEE ALIVE

HERBAL AND NUTRITIONAL SUPPLEMENTS, ROYAL JELLY FOR USE AS A DIETARY SUPPLEMENT, COSMETICS AND FACE AND SKIN CARE PRODUCTS…Owned by: Bee-Alive, Inc.Serial Number: 87534853











SYNLUMIS

Pharmaceutical preparations for the treatment of dermatological diseases and conditionsOwned by: Sol-Gen Technologies LtdSerial Number: 87535112











CAPSULBLUE

Ophthalmic surgical liquidsOwned by: EXCEL-LENS, Inc.Serial Number: 87534862











Q

Pharmaceutical preparations and products, namely topical preparations for the prevention or treatment of unwanted or excessive…Owned by: Dermira, Inc.Serial Number: 87533346











ANTIBIOTIC FREE ALTERNATIVE TO ANTIBIOTIC OINTMENTS

antibiotic-free ointment for treating traumatic burns and woundsOwned by: Mark Thomas Finneran, M.D., Inc.Serial Number: 87534888











NATURE'S NUTRI-CARE

Dietary supplementsOwned by: Abernathy, Shaun AlexanderSerial Number: 87534930











IV IN A BOTTLE

Electrolyte drinks for medical purposes; Dietary supplemental drinks; Electrolyte drinks for medical purposes; Medicinal…Owned by: Rally Brands LLCSerial Number: 87534933











IT'S ALWAYS 4:20 SOMEWHERE...

Medicated products; Topical analgesics; tinctures, namely, herb extracts; herbal anti-inflammatory salves; Dietary and nutritional…Owned by: Terra Tech Corp.Serial Number: 87534944











CORRUGUARD MEDICAL

Syringes sold filled with MEDICATION; Clinical medical reagents for processing human whole blood and its components for…Owned by: Gray, Robin ScottSerial Number: 87535018











SERENITY KIDS

Baby foodOwned by: Serenity KidsSerial Number: 87534519











JACKSON GALAXY

carpet cleaning preparationsOwned by: Little Big Cat, Inc.Serial Number: 87535047











BALM OF GILEAD

antibiotic-free ointment for treating traumatic burns and woundsOwned by: Mark Thomas Finneran, M.D., Inc.Serial Number: 87534799











HOTCHLAND NUTRITION

Dietary SupplementsOwned by: DONG THAI DISTRIBUTION AND IMPORT COMPANY LIMITEDSerial Number: 87532250











AVENSIS

Insecticide used on golf courses and greenhouses and production ornamentals, and residential turf and ornamentalsOwned by: AMVAC Chemical CorporationSerial Number: 87533287











PREVIA

Fungicide for golf courses, residential turf and ornamentals, greenhouses, and production ornamentalsOwned by: AMVAC Chemical CorporationSerial Number: 87533301











TWYNEO

Pharmaceutical preparations for the treatment of dermatological diseases and conditionsOwned by: Sol-Gen Technologies LtdSerial Number: 87535093











COTRAXIA

Pharmaceutical preparations for the treatment of dermatological diseases and conditionsOwned by: Sol-Gen Technologies LtdSerial Number: 87535098











TWINEUM

Pharmaceutical preparations for the treatment of dermatological diseases and conditionsOwned by: Sol-Gen Technologies LtdSerial Number: 87535103










Today on Verdict



Unprotected: Lesbian Co-Parent in Idaho Has No Rights to Her Partner’s Biological Child



SMU Dedman School of Law professor Joanna L. Grossman comments on a recent decision by the Idaho Supreme Court taking a narrow view of the parental rights of lesbian co-parents.





Ask a Lawyer







Question:




Add details
120



Additional Details: 




					    	1000
					    


Ask Question






Find a Lawyer
















Lawyers - Get Listed Now!

Get a free directory profile listing







 



            Justia Legal Resources
        



Find a Lawyer





Bankruptcy Lawyers
Business Lawyers
Criminal Lawyers
Employment Lawyers
Estate Planning Lawyers
Family Lawyers
Personal Injury Lawyers
More... 




Individuals





Bankruptcy
Criminal
Divorce
DUI
Estate Planning
Family Law
Personal Injury
More...




Business





Business Formation
Business Operations
Employment
Intellectual Property
International Trade
Real Estate
Tax Law
More... 




Law Students





Law Schools
Admissions
Financial Aid
Course Outlines
Law Journals
Blogs
Employment
More...




US Federal Law





US Constitution
US Code
Regulations
Supreme Court
Circuit Courts
District Courts
Dockets & Filings
More...




US State Law





State Constitutions
State Codes
State Case Law
California
Florida
New York
Texas
More... 




Other Databases





Legal Blogs
Legal Forms
GAO Reports
Product Recalls
Patents
Trademarks
Countries
More...




Legal Marketing





Websites
Blogs
Content
Social Media
Local Marketing
Paid Ads (CPC/PPC)
Lawyer Directory
More...












 
                    © 2017 Justia



Company
Terms of Service
Privacy Policy
Help
Marketing Solutions










Wallet-Sized EpiPens : AdrenaCard























 



 


















TechTech 








Ideas
Insights
Services
Reports
Dashboard
Books
Assessment
Keynotes
Events
About
Contact
Login
Logout
Copyright and Terms
All Categories >










 















Wallet-Sized EpiPens


										Score
5.1




 


										More Stats +/-
									





Hay Fever-Fighting Devices

Customizable Allergy Cards

Instant Allergy Tests

Food Allergy Bracelets

Allegen-Testing Food Devices























 40SimilarPhotos











The AdrenaCard Makes It More Convenient to Carry an EpiPen





										
											By: Katherine Pendrill - Apr 2, 2016 
											 References: adrenacard & bustle



										Two students from the University of Minnesota recently invented a wallet-sized EpiPen called the 'AdrenaCard.' While EpiPens are vital life-saving devices, many people do not have one on them when they need it the most. This new device solves the issue of portability with a smaller and more portable design.

The AdrenaCard was created by Tyler Ebert and Christopher Kuehn as a way to ensure more people have an EpiPen on them when they need it. The new device works the same way as a conventional EpiPen in that the user injects epinephrine directly into their leg. However, the AdrenaCard is only four inches long and two inches wide, making it far more portable than comparable products. In fact, the device is so small that it can easily fit inside of a wallet.

With more than 16 million people at risk for anaphylaxis, the new wallet-sized device could save countless lives.																													
									
			



									
									









#1 INNOVATION KEYNOTE VIDEOS

 
					Join 10,000,0000 people getting Better & Faster
					w/ Jeremy Gutsche's Innovation Keynotes ➤

 



Related
Top 10
Slideshows
Video




Pro Services

Innovation Accelerator


Innovation Keynotes


Trend Reports


Custom Dashboards


Future Festival

Free Resources

Innovation Videos & Books



Weekly Trend Report


NEW: 2017 Trend Report



						Get a FREE Report
					








Peanut Allergy-Eliminating PatchesThe Viaskin Peanut Allergy Cure Sensitizes Patients to Peanuts

Emergency Medical HighlightersBe Ready for Highlighting Emergencies with the Syringe Highlighter

Natural Allergy KitsSaje's Natural Allergy Remedies Use Aromatherapy to Heal

Carabiner Allergy Injectors'Epi-Inject' by Maria Pitallano is the Latest Non-Stab Clip-on EpiPen

14 High-Tech Allergy RelieversFrom Personal Nasal Filters to Bacteria-Banishing Air Conditioners

65 At-Home Wellness InnovationsFrom Minimalist Scent Diffusers to De-Stressing Bath Kits






								Stats for Wallet-Sized EpiPens							

Trending: Older & Warm
Research: 800 clicks in 68 w 
Interest: 1.2 minutes							

Concept: AdrenaCard
Related: 52 examples / 40 photos
Segment: Neutral, 0-0 
							

Comparison Set: 19 similar articles, including: customizable allergy cards, hay fever-fighting devices, and instant allergy tests.																			
							

Related Reports: Allergy Report, 3D-Printed Toy Report, Allergy Product Report, Online Video Report, Discount Store Report 







SCORE
5.1



Popularity
Activity
Freshness









PROContent
CustomResearch



Comments / Reactions [+/-]



Bookmark
Comment
Must See
WTF
OMG
LOL
Cute
Nerdy
HOT






More
 


 





Questions 33 time: 0.1123 , e-time: 0.1146

PK     ! �H��  j	   [Content_Types].xml �(�                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ̖]O�0���"�N��&��r�冴N���'���d���;N�A!!��H�����?d{v�`Mq1i�*v\NYNz�ݲb��&��H(��;��;�9�-6RAj�*�Bg�'�+R�8�}��7.y�V,��L�?�������.�k���jnI�[�⢭�Q�6�s;߫�`���h)����SO�&[���MMZ鐾R�	��倭�Mf�
�+�T��}T\y���,_�����ZK���-D/!%Z%kʮ�
�v��8�:����p�`���x0Ng�� ��nd8��>���fh�e�������D��u�E�����Q<2���G�q���{!���vν+
���Ak|`��c��5E.č�1��ֺ�.��;|%��"��9�m�0��U�Փp���%����A~%(P{�y�R��  �� PK     ! ���   N   _rels/.rels �(�                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ���j�0@���ѽQ���N/c���[IL��j���]�aG��ӓ�zs�Fu��]��U��	��^�[��x ����1x�p����f��#I)ʃ�Y���������*D��i")��c$���qU���~3��1��jH[{�=E����~
f?��3-���޲]�Tꓸ2�j)�,l0/%��b�
���z���ŉ�,	�	�/�|f\Z���?6�!Y�_�o�]A�  �� PK     ! �G�N  u   word/_rels/document.xml.rels �(�                                                                                                                                                                                                                                                                 ���N�0E�H�C�=q���P�nR�$��3y�Ď�)���"ʣ���0]ε�+)b��@p�U���[�|sObҁ&���j�5CsI�U�=�E蘔��#����0���9ɥj�P�e��@� XQ5�A����6���f�~ڵpNn���'��z"\��@s&�߰C�S��(�wSm���I�B���ܹ����+ ��63����:D`�v�l?�d�p
q�r"�L.Mc5��%�>�ɠX�t"%��D��֍�:�v���ck����o���Ҏ\�h\Ҁ���)�2 Ѓ�2�  �� PK     ! �wF{C  �^    word/document.xml�}�rۺ���T�;���s�d��~�:�G�,;ql���g�;��DD$��R����z�$��b�v���aw�Z�L����5�?��ߟ̘҄ʸ����D(#.������^��4M�`�X�������_�ב�	M�-D�z>�zk=}��U�,�Y5塒��j(�Wr4�!{5�*zx�W��*�,3�ףbF��ۥw�&�L�7GR�T�_��UJ�$�O��C�p�0�����ȿ^�J�^�bo= �'��-��B���-�@�K���b>�2���y3^�d��I��d���ԯ�G��͏/7�e�Q�GiR���w����X��.C����HR�ŗ/��Gs�����A�}�����9Q2�~���������dǽ� ߞZ�s��tj$0_���01#2��ԉ]�/���haN����X��_/�X�A�k�X]:b#�'��;��R��q��^��s��f����x�凋�\���@/f>3��_/�0j�o����3ju�K�u�B��Φ44��*�15c/ι,���C1f	���HO��kbo�����+��X6��fyp�3M��#�	q�nn�7K�e?8������;�h��o�(��n���Ψ��?��f��u3{����w[ˇ㵾��z4���G_�;����~븽����!�B卑������-�Z�d��RH��5���Cf�y��t���f�:�V}��/W���uyU~M�yu󠾼��^�y���~z����_�����凿��0m�kY��}��� �`y��P����ircH���3k�0���])')�}�BJ����n��d�O�|�.����hB���ptF2I�%�@1j#F���>�+���A���A=�Z�%�1�F,5>(@f���!��lݠ A)S0�	��������>������4չ����~��n�ZU� !���(u@��ĆEL��L&,Y��Pʨ@ES������#6�J�hF�������(:���A?�&rX�P��*�Q�Y
��)Q� �K��h����?�O,@1�p�C�mPj�'����m���0�0�f����Y�q#Bp��Fx ��A$�>���A-Ͽ���!Nٔ��c�Q���Tl�0�3n뿠��
R�*4P�P�װy�(z�w���cm�W���g=���Qv�oY����9A�M��UQ�X��1&@B!2B$��ؤ�)��ݍ �=M@l�����r8$��(%��k�	��qG�6.e�u�r����>�Tr�h
d����^V�����vU�s�^����%h�]�����?0��N���������S�1Mޮ|��"�?&�4�`6,D;��~Ы`u����w���_G\e���Qk�N�c����	�u�կ�R|b��`׾߭[\[=X�W?�����W�IJl��8��\��n�-�P���}��|��wPky�_����kgD!���]�x��u�B}�������B��F�������1�Dh�S/�����^���m����_�q��K}>����;Kы��F���@6>�v�ZN�H]��m(���w7%�Q)�VB�,D~��8�KP|[(+[˵�a�u�.���H�'�����K�C3�Z����S��
����`K�.�Z���by�;�Ń&`w?sm�o)�U{���K�7�����:	��Y��6�Z��b��7��$h���q���[�]�����E�Rո��瑁�uL����V��
�\3R��s�G��>w���V�أS�p�/�/H�Q���rD�(�wTQ�q�N�W�&��WH�w���
	'�T�zg�R�����i���9��[A`�R��2A�\3�B*��_��O\���{�EU\�.���7��US�L�{�B*oy�� �O��ɜ(9cK�_�7��#J���qBc���BNiʌw�q��x>�c��4cGl�Cc���H��߭t�h5e�4�j5�d'|r�gL��1#=�� Y 8���Jd3�$K��cS~OwZw����B�i5FU��ӇB����Fŗ]��yP�v�;�wA������; =��R�퇊�@݌n�ۤ��$��b�
F.�'\��"�QC���:� � :e"c�B.�f��T!ӏťf{��G�>4@�p���_�C#K��\��H��e��-?h4=r�0�L��e��#��+9.��P�VP�*%��B�����ay�C�z����ӆ��Qؐ "A|28�s�uj>����k�9�:;��sA?��GnX���ʕ�\p���)dIƥ�]+8nwA�at&�L-*����t�tL������V�q�D�e5)>әp��%
Q�j%�WoE�Un�.�9c�n��!b. �0�頼��z�=4p�n�Ѱ
��?���x�f��0 n����."��x�|�;�k�f�T�i�L��\:�e���8�,�R�N�*�4�YU�')�h[��.���W���3��3�G�������IA��B+$��:t�Α��mU��\*�.I���G�x.�r\9�b����6�s��bX�}��S�R-�ͻ�{҃~�t�'��}�>] ����)]!�������'���^6�j��hs$�%�q��"N���&F��
ϸ��0�~�7ɡ���re+#p��k���#���y���9������8�Y4��i���Z*�w>A���I���C2�K�ܡe��b�v��هM��x��,��p#�N��ڞG��RA��,*r6W�}��!f�0�&R��YhK�ʝXL�t�l�fG�\�6?�*��-��._U�U#��16�Aw��y�НpD��Oƽ����6�Qj{-ҽzxts�/2�&}�b�g��x��n�&�Mt�t j��T�g��[�H��v`�Ωu�?m@��0�����Z��Gڶ�����q�އ�0�{��zQ����T���n��ŕ5
=�
�*�f��3�����=;�r�����p7���7�=���ƒ��n:@#|,�Xv]�a�68|z43�0�&���>��-4��h�{�Ho�_n��޺�ӉbT3�nY�sq����4~Wj\�nH���a
��}rɓ$�(�!rFXd Ÿ'kp8�#s�'*�
Β
��Pk�l��J��wQu�w��	�����oޟ�����T��(��u���,.����s�x�	X?b�\*�g��u����Ex���6}g�������vB�Nk�2B����1S���
��{N~������rM ��f4���2�a��r�� G���ee�CԈ��B��L7t�R��'�/I͋꼸��B���rv��!g�
r����gg:O�VTF��VE�V��邎(���ȱ�Rc%se�J�h]����N58�|=��UC�V�M��(�fN���h�d9c*�k����w2/��1�qiF�T$� 5H��u���A ~�I~1�ߣӞÒ{�J�/��Vb����j���3�9���y+�tȃ�8ns_�:V��҉��
9L�'*"�@�������;h*����;�2zu����*@h�p w�~����BΞ��@O��T��-�����z�3���l�+�"��;`���X����?bV��>=W'Ո��)u�I�Ɗ1�-2���&�$?w(�� �G��eZI2(n�:#Kͺ� ��g�֮-Lr!�����1C�&���^�&�=�zq���8_0Q!�"�� �%^~s�4z���M�PWE�DgXئ��ux"ӓ"�S��G/�.���C>��Q��ec{��m\���G2�1i���ˠ�a� HK��M��4�Q����e�|d����3,�c�R�H�!�&GzN�fẃ��PH�͉�i��8�"����n��	M4w5���=Њ1@��}�d�f���k��k���b\v8���xT!��4�3N)O�a�4z2�暩�|�)>���	q��8��Du����i��@���$�5�=C��¦9����Ї̈Pf��\V3/:�R!~,�!�@��a*)�>��D���\kz�����V�&��#��tA.��1��N������������G��4,�g�v�I�Z4�0�%)��k��糀a,S����N+��gԬc�"[ϱ3,ͪ�Шc&�m�أS�+v�]�v����(�AUr�GE��=�(;�$L�"�ܾ�����������	S6�ꔍF�-���NXڂ��(��6�����5N7J�����$ǉ�#�uG��}�#~�:&�L)�&��A�
�Z�*�4sg�5k,����;�$r3���Cܝ8�u.YRv��8)&c��U�#����%@�q�"҄�⼠�:����m4�h�`��~���^��l�Xr��̈�c� Bժyd�Bi�^Ѹ��l����>�'ܣE���k�H�2 �\JQ!W���b'��q�;�ey �����KA	��#w��2ZG����|r�m9�3*��³�2ѪQQ����˻*υ����j�y#��םa@��͍ظ���q������⌼��]�!o/��p����}�n�\&��xN��'s��l����(-G䌫1�,1�j�����85�����NS�Č&:FG��xS@�0��)s����z��)����3w�l���X&\�P�|#�H�C:�4�C�}QZ���y������{R��bB����`��{[�Q�
������bh{	S�囀_��S`��rEo�̀��2�q�^8Sܧc[/�L���=4|Ne,2�OuJS�Uș���D�	� a���u���A�������u��x�3�72����Ԋ����O�Ly�R阼����}��xL�c*�L�+�H��n�q���\*�.����dʐ�;I�9�S�R��o�F,	P��A@�H�0�]+矂k��p����F���t("����wT+.h�L�U�|�R�R�����q���5`�A_�8�qH)'/�47�sa(hB�-Z֓^�9#�~Ъ�v%�d�98�y�E�i%�u/[,����'2���t� dnALUb�|B*V��"�z?��
mie� j�3p�#�v��lz���/�'�r�;k��p�q�=�#7,�c#5�Hq{ha������C��.�v++��
�w��cm��M����F��JG/cl5cQ��At\�[H��I�����LK���d��"�7���Zm��i�c�8�
Y��yPQ˦�A���`L7��ifp
���+ո�V�� D�F�F6��B6O���"˖iH��� X'쉜��Me�x�ApRv%Øe�(��>v����-*�����B�k5.3�p��RI"���Dn�8������2���@m��N�����d�k�6�_�J:s4��m��@���X�"Pb�}8�;1WP|���&����x� ��1Us�����Ƴ�}��,(3�#�B��l����gb�0����t���fc�� ��Y�#�Ҩ���H��f�HU��@��S�L[6^V
�U0�.{�VC{����&��av�3�
��I�Kf̆$:Fp\"��7���E�H~U�LG�N�.�EZV�,Y_��-G�#?�b(���#�j[��%0nX��M��ϳb1u"ks���GPoc�/dt���=Ί��9�s��a��ܴ�,E�6rM{���9�\L9j����P���Zx�n/����*��gZN��k�vމ
EO��8W�dA�J�3\xޱ��C�D�'�t�~��i��4K�2g�n+0���s,�D����.@gT�I%P1:8�S�dN���Uɰ�3���*ƫk#�w|�o������,� �V�Լ�D2Ó'�rX���*�m����鹁����@�Z5����e���똑w\�1x��\V�WIW~"A��l#���ݪ:��y,�
T�����#)h��rk�v����=��Gw塱�44��).t�&��A��8K�:28M� ��䇅įmrţ1#=�+�0��1��)[P`��zD�$�OG��-K�(���\���M;�~@��E�\B�FX0���n 8�Ϥ-�pF��X�A�k~�\/�Lȵ��`��$2��M�X��X��9?d`�5q�9��TAX�Ύ�~��P�t�OgmhbL(:u 5�[��L��aC��:�HS��ELO?a�V�f�`�i���Lrۦ�w��n�7��G}t%���%���^�^��-G�q��!�L�-�~�0!*�B��U�a���ː�B�X��#�$���@����y	�;g��i�Kv�G��o��A��8�xN���8�P��h)&��\�zAZ�������n�{rI��1��w�b��0\����@��Bȑ�S�y�����8�&@��֦AG�	
j���^�;�8�f�}�u����^L�/N��Y�� �g�TJ�)�9�:�S�o=P;L�g~FI��w"9�y�-Ћ������)r�d���̦��+���6�m�0ϊ�mit�Y�˦\Q-�];�����HWI�s�҇ �
�\3�ב��4��1�m�����[!�{gd�|f����Xvg�߂��/��&��a�u��;9�7����':G������b�ԡ�4>�3]����8�t%Øe�v,�Czb��XD�A(��Lz��W��ڶ�O6�����kd�'�v�Pt�r��
1��8� O~�ț�$ZR�*RAv�=ܝ��ұb,��BN���_!���ʋ��Q�6u�%�D{�;g���G�LX�I"�ײFvOs�=�d�cR7��¶�x���#^��/�3m���K��,.���z�v���3�#O�Eg,��,�_ P0&0�8"@'RF�)V�tK��G����5�F܀��}�������Yl#������� �I����F�15{��� ��(ز�)����N���[gsr%i�(���k��y�x��q}���RQ����t��0��D�f��b���C�D��g4�Ǳ}ʝ�a`��1I�]�!
C/aT�k�
:��X����Y:�qbs�2tw\�v�En��Cx�O�.��19�bB�,yu��p�8){�vDg�Zh� UH �6���!�s�B~�Iz�v�תb}G����;G,�~�>��#0u�R�֜9�3�EQ�c�:}S	 �֓�47L�,�y��ڬ���N4��#��	��\�3>bdr&B[��#2uY}O����^����]&�ԦV���-�D�\M[��eJ�껩���b�`����fDZ@�>ejca=4!w�?�z�0������C�Niu���]��t��iJ���5��B�F�xp�����m��!t����[�2��M��(�	�>p�R5��ۉ-�6�H�(Xq�%*��b��mKE>�o���j�;��n7ڤǄ�����ʥ�*ƫk#�w|�o���UO�nb�\}4R:Y�a>�8���� ����v�3N)O���&�	���ɝ}淢g�H�dKջ��\&������Q�J�Z^�\���}F���VǢ����F~
���y:T��R�i����aLٶ�]�Ou~��|�>w�K�3�2-�t!*ft�D�~�/��XQ�"r"gL	*BF2ɱ�[��-�tY2����01�
���{��qUι]��NS�7�NU�Bnx�p�VȠB�����Nհ䕝�����O�LҚ%�~uÆd`���ֈ�˘"��!Ta۞�Dy��öI?��w��C�]�J��N���%J��؎oJ��߬RM��+F��@�y��OA��_TT�[�|=>;:� ��[����P�9�B*����5H�h9,Bᇵ�v�ޞ1L�*�O��P@�����VME_�s�y���C.V%�}�>Wr��Ū�▆\��.[}�;��i�Vm�L��pc�����P zRdy��T2�C]F�=�E�8���Om7�-	slX��F!:�9|��c�U*s��!F!4�]%��a.�
�k�*2)*�+�}}?kK���>T[��^�Ҋ=���'뽎����Q||�x#S&�$���N*8zG�#��r�ȉ���B.��9!OA�N.�б��ȅT6��&bX��+(��[w�b���7"��W�fgc�rX!c�:2�餋�-�G3 uG?�Cj�2v[���!y�������H '�F��7ț�$*N�l�9B�'��c�%`(]�0��A�H��d��7�ǝI�ᑂ�Ըd�n�	�ns9�g�V��]zǧY��^=��%�� W�k���4���2m�\�+�eP�,``�C���������5C�
G
6��� J2�d���bĒ͠,g����\j����;�����d�Y ��Llu�4)rK��j�?:�
���[�������d�1�׌�)K�L)�o'X��K��VB7�9����A�":~��3>3�#�RXA�lUV����BC��^����	�c��s����P�G�&[�_�Ύ��!2��.�Nb�gh�'� Uqَ;���i
P�0:jG�p�Bp�r��u �����6����7@BT�B=4`�Ϯ��"�~�Y-=Q��]A��t%3N���SM$5OW��l\����@��f	3����ef9�nx8�2�N��)�Z^�V����l����J��U.0G���{mRo�e�D�Ƞl�����e�7%`(��y8��Sy�~�z�v������h�n'1�S��RW��8<	9b�yU���wΧ�vvD] �8��M��1�;�T����8z�h��q*�M{��@�eE����j�n��M�?�!��6#���\��D8�D�)t;dǝ�qL rD94���G��j����:
�( J?�����L��=��@������Do�g�����YwQ5� e�hЇX�m>v����8[�~4�
�l��D3�"<6qF��A�A�,���ݠƣ�j��F�q�)�an���,E�@��A�STDEA�eZP�ؼ�j���Ii�~@����e�� 2.0�9C������{�2Wc��Z����������̗�r�ْ�����w*�>����u�~=�ﴰ�.X�+	R\����2M�l�Ms��>�{RM�**9��tAw���ݍ�~��P*���'%F7t�*���="���0��C��h1ɴ�e��qA*�cT^���9YhLz" ���h�H�_.U��\���\�S䒪	9R;	B�5*&T˒!6=LpC���bK���xAS�n#�w6 f��4O�`�&�s���X��1�[��1B��f����lWpk|߂����l	�����,'G��li�s>��c@s��)�T�eX����=��L�
�Mf��׽.�����˚��y��@ï�Hi�XK�>A�ֹ��+ƳH����߸�Gsk�*�B��eU-��I���%@?�y{����БDGɭ��J�`]���(�O1? l�Ū�˶���$�4xW\��׬���v1�`7�Lm��_C����ΨѢ>�T��n�T���/�I�n'����D𽎷r��v
�=pVJJA��a~�k�x���`'"��@���7'_�dB���Uj|s��;�hE����ssC�A����Xar��&/M:4J��
aF����
 ���0���Y@�~NO!���=n��D�$�C�_�o��A���OzT%�qޝ��oO��r2ߎn�,�;�h@�C-�dUc��!��C*Y�\�g_!�25/��d��p�qaFѓ�&jC�u���'�j���]p���[L��k6�'�0Wc{��E���c08�.�E*s�"��@�{�P'���U�	�?rU!C��:.�c���Y��iTX}����h��űTi�P��.覦�xj���j��)dIƥ"]�'lFU�ޜƸ$p{\�d�k����hZ!�����Bl@�f�Egĵ`Y6Z)t� �����n���1v{�hz�ϟVw���h�����7LqMǬصƴ	pF�fQT�Z�^o?@��!tFUf�]�(����1�br�Ϙm�n']hc4ǅ�D�,�Hύ���� �op�'�XpA�$�i���1��Qi���f	+:�ɕ�_��}�p��R��U�% ^�*�K4.�َ͋yGX�^�v�{2���(�q����"�\Y�Ψ:�(xa�v���C�r%W������n���m$���{΁OOB�� v�7�Sӝ�v�K��}y]ǠDh>�U�RQ�8[��כ{A�&��j��I~6��IQ��VH��W;���ْ���"@�Yd�!G�L$TD��wΧ��hݛ��F7vn��5Sr8����p�J��V�߃j�Ǉ,2 �:&�u���փ#ws����ҿ9�J�jAŖ2\�Ҏ�.�V?����9��X��_@�-��?z*8���Ϯ�GX���Pk�-��OIgv���f��R��8���b�$�	�f0�K_�,gQ��V�3
��/�.������oVWBt�Jԍ4��s��]�-�u'+?�e�3�Ϙ��fy���G�jS�^�(�և*u���m���0T
J�F�R[���f�����Qy�0z���  �t�  ��	ۃ����A.$�ո�7��n��1K�K�j�V�WQ��Mܪ�Fi��鄋��P��!`��X��N�Ls��f��#df�R��D�zRdy��T2�C]�X��%��B�m��O��6�s�>a>jDK�xmr.�?{�ڜ8�m����W���8Ug��~�����O��-��-1����+�@��I:�����吤#kiｶ�KM� G�L�
 �E0�(9���TD�3��K�D��K짰�۱�qh�ˈS�r."�M.�-DY�6�
N�M3.��(�-����7-���qPӇA@.��	9�*�[YF�}�Pr�"M��J0J̿�5r3ΖvV������"��)pP^Od��!�N��3Vh��>�F��A󀼥B�2��0�\c��jhb�|���8Q�P@6��8o�CGޅ��J�s8	N�G��T�(�r������R��t�	A�������P�%�BT����9Jy��8��hW�̂���j�^wd�S)���
��xG�ٍ�5@��Ϫ?�}��+;�uː!�����ʚ�Gq�� �s��2rI�99fB3Ez��O�m�uЃ���H�PMW���Hq�k�2Q#=z˷���hW��%�4�v�;3�ʉ�YeX�5:(HEGLfgp�ȃ2�k�&v?~?�������;h�72��P2&gT�*W��{A�t�U5�UJz�ļ��=���_=��RLY��35�f����EUFF�38����n	�7
��c8�i�����@�}Q��mЊ9��__֜��:�-h4A�7�����D����9��hϫ��3���������s�Т���xۢ�z~�����aF��ٜ~J�:�-rM������99��;��܂�� ��(�,-��d�s=_}��h�و�n`��y�m�J���ʰ���[�D���Z��AHp^O8o�&C�'f��ZuQGr����('�皉�f���bK���iW�����):3k(�l�+pEa �zN�fg ?8=�H邌��� RTG	��7�{����KbJ힅�u�7��j�x��#��N���>��O�D�UZ�.XZ�(-{M�v���B�a2���ɤ�����G�ˆXj:���3v^�%���h�^��Wg�'���L6��#a�V�־N�86^�褝a�_�: ��5"ݥS�as��;à�c�Fh�Q�e2)۸�r7t؇����,�/���t�4�ɱ�)�C�#Pm�M��X+��ZI.pa]ҩ�d;%o�m����4:q/�!U&k�L
��z�اz^~ޙ�Y/�%������$8}w�(�˔K2Њj6Y�}����mr*�e����m�������Uu^���:�ٙ����~kǹ_3�����]W_,���sXQ�
	���(��5.X5�S+�8�	T� l�!��׉e���UX:0%�m�|��OL�D٢�s>�N[/�.Um/��Y^�sgV��������E��I������ӷ�O_I-#���H���=2,�-Y���a���w�l��k���kE	M�)��.U�MY/�.d�%d��0��ȴ�@�]���p4E~���W�"?�J�1�~�Q�� [�?���*)���z��y�F�}�4�A�a��m��2�wNA@��\� @�>פ������V+�g�ϔ%�[	�/We�5t���������%���P]T�')��2�D��D�Ua��g� �µ�������',�>�X:s��Jy	�Q	a��oWe6c�b�O�Mx��޻��9�vBO�	5ᮺ��[&���b���[���/�3A�,��ܑ�N���QpR�0p��t�R�z�{#C�a@�''��*�������f�� -�.�Lq1��������r���N�r��t}Z:���ރ�����L	����GQ����4]�\_�cY0����H���GsU��9��Q�rm�u�^�!ƹ:�Q�ݦ��䚘5�t2���s�.��E����l&�~�`o���@|w ����(V֒n 3��R�\�� �xwy�k|_�`��Ef's��q��AG�{��,S�����k�Hk�������p}�MLF���(.�d9�����$lf����ӌ�ii��ج���ff�����hZ���5�h��N�����-�Y��D�!J�Ʒ���I\De99�ٌډ@�ݳt{�e�Q�%9N���4^�o���9Z�J�����vŭ� ���q#�&����ng�F�ںR�	�۔���D���"���{VP��Ltxs�n�bîdNu%�d��Jm���I��j��r��E���W�J3@gh�̰�i:�75��,H�L� cd�����U�5"��㒍ˍ�̗� �u�o��8��M�2��xK���Mt�4�����Bs4퀄"^�d�9�R��q*�x�E%,�@��T��H-�~�&��^�$U� Α�:��
��9��>��O��St6L��p�$�8�ν��\h¾5���ܜ.H�.l���f�ա�}�߭0IVD��@6��#G_�ņ����������;�=z˷]���>'o�~���MC����A�5gu�ω��������Rq�ա�^�k9,#+W�՟G��ȥ��<2��f�i�+�1���-��n����%��}�3%�����{�X�����)��+u�ʖ����JEY>�e�Qz�����z��A�=����93�sw��'T$4�٪cD3@4�5��R%Ӹ��C��5����u�h1�w��v�bє�XW T�����ln������zHrYT()ئ���B=��0ܫR�Ȁ����us����\J�]�s(�$F���W#�HHz	��1�[��[��W��m$!�0�,8�	�e��2�E2�(͠I��xQh��Q_�� ��ͱ�C�]C�K��5��F�R!hR#W5����
]�W�w��w*e�G��q4>�������e�:����� CNSd�E�F�N���T3M��H�-U�!C�8����S(0tû�aW����Z��1�s�6)��ٵ�����d��ttrk9��p�YrQ	����kt�r \���Ӏ��3�V��ٯ�ߑN��y����t�d������䯓���9��\ ^�ޭ�����̥�4Z�h�"o4f���^�[Z�=*�Vz��}:�lvW盍�3pAEd~36������_�EJˀT�%F�Ie�j�k�U�)�����~# 'S�q�lk�^��k��4]r�l���\n�p�c����t����}4�B'M��1���td�S#�8���]����MfS��{�8s-�Y�l�J�t�Cl�1՘�~�NH?5�[�@��t���әٙ7v��:k�
ݣ��-E�#~��$�����%^٥��K�\T_�m���8��m��d��X�~z�e�ܾ�|�5*��[�u���w��^qI�����~Y!v�mAnܖn�S�ȕ,4���/F.�����ed�F��`eO|j��7:��>�a;����'B��ϪGMS�`w����c�T�A,�e�'2�����! ��ɕ�l��u>�!:�:������*������o�=&a9�n�q��~
No�ƌ�[�|.���'���~���x��|;��o4�Ay���f�G�֑��V��r��}�.�(�ݜ]I�ʱ�eA�hL��Q:�����UuL:�%ku}AwL��ՙ��?�l�n��_{W��`&��c>��So	������F�IN�"��\*�Mo׍�[�(���
���c(�ѹ�2�&,�VѤ���P�O��$�Cѻ��`��7��O�G���*�ҍ#���	9�r��0Po�i�h��dX'ג��N�)n����c�[��8�IA�Qv%GL��-��v����d�E�0J�/Å[m?pڅ�9�o��|'�F��9�
\�Qj5Zd�Ә��2g����U`��&6��5�U�S�"� ���i4?�~9�P�2���N��b���������n߂~R���}?�k�=�|둽xR?��;}�5R��t�9x����|�U��&z����(>sQ#�eR����'�gm-G$���ݦ\ݦ��Qn̆x"$�;�:a�U�q��N�|#� �QiAp�>�����8�.؜t�$eZ���-�����86J�f�jlQ#�5���gmռf������9p��̖���r"&\��5_��&N��~�|H��-93tN�J�~�frI-�B/��A���ڧ�1��nX����p]�`xn��Y��AwTh�����x���� ��'铊o�E?���2#8h��;xC���j�ʫ8D^�k]٬F>J�9'525�ue>�h�ǧF���:ܥ�a*>)�XI��20X(�����!�tT�T'�����s�#i���Ku9��J~[#	]��>*?�L2�SYq��,�-��O$��9�7p��"��=��h�c�eLE�ڪ'v������J�	N+*��c�G�6�����owNZ�Ӯ�s^B`�,�[�ѼȘy�%�E)�����v�B
be��Z{#HͰE��aϘ�ChZ1��oA��@/
��ǽ(zEZT-��A�f7�v�.-�ڒ��4p�����M[��^�]���r��m�3׷\�Ǩ>�B�і�d���+s���^�|1�1�	�c���g�v���"J����}�U��s�0>2�XG��mD��c_���J�y��?�ϣd�qy����	�ή�XͲ�~O��L�I�е�E�l�F�NGсK�}���8p٧����Ūݶ�l��re��Ȑ�z����}"��Gs��d��x���'��Hi�c˶@����ާS,���H�_/P���&A�z�B��Gp��|�C�����W���Յau]\�{!�a�ȩ�"*[s�
��3��@�L�\�7d���Ly:��2qa8����������?�VW/���v
�%�RmN��"v@|�"��oe[ Gj(3&����ZX�=�����J��0��Y\�(�V�ɠba���X\B��֯��܋���Sì��1uQ~j�����&p��G�bgp�il�*'�o �;�=L!�霊o6�dH��l��b9�l]��@��s6�����\C�8QA}𝈋\�߇�r!�ݝ����|���t��]��G=��!	ub�tC��:gw�����C����λ��ã���F����i\#W5��/���j�^Roei�k�w���s�3���EP�.�P�R�I�Ӊ��CE��V�FY<1�q5��9&d۳�����خAr����W94�52�^�Sd���'�1e��v'��	�Bx��Ѭ���l7ɀ�⎜I9��_w��q!���6X%co����ѯ�R�N���9���P���tn��Bcu���vut�:�:4:��3��f7ac/�,h"1��E���G�O���sG� ��=���m2�)�6	��d��ò�bcX�(4�bD��F>زS��F��cgnux��*.w*e�GϨ�)�q���C1�5ۍ�d[ރl�;�%�,��5zO|�����״�r�#�\�ȫ��&�����a�Q��yn����S�-g��V�#�ؖ����W~5�Z���wS6֟�J��Y�~X~9��������˿��n�(���/�Kp���XFo��_�����j�>V[V>�d�(̯6A���   �� PK     ! �#�e�  �     word/footnotes.xml̔�n�0��+���	��.
�����jw�5&X��6a��C ٶ�����3��3���Uu��I�9I��DBs(�^������D�3]����V8r���6o��k��E��.k�I�����J(�JrJ?�b(K�E܂-�&�{3�p�1�a��p�=��xX�Ụiױb��1��峬��"�^�Icu�CLFA!$��!��Yo�о�[Q�Ю�f_�WixX�ͱ"6��Z��Λ�Ҳ�=��E��^�qbBO�H@��H�7�D1����Ԛ��&���of}�p~Yh̞&ϣ�뗑~�O�vC>,͝'�b�@ų��˞kT�#���Q�����ʉ��oz8a�e,�-Y�d�t�M�ӊǜP�^OW���m-Eɚڿ?y[��ُ�iy�aq�qT�N��ojz��F�	�Y�ċy���鮕�������%+��p�W   �� PK     ! �&��   !     word/_rels/header2.xml.rels�ϱ��0����`�7N:�㈓�d-�[qLc�ؾ���5ti�Í�����_�/��+��ƱUp�|�?A�lpL
6�0���L+�ʋ�YT������%e�y�M���2���1YQ�В�SLFA�L�E����i:��˛
�|�� &KE�'������˗ǆ;   �� PK     ! �cP�  �     word/header1.xml���R�0����ܷ�2R/�T{�xx�B��4I ��.�jgj�v����%����"��u\�E�LQ�q�J���b4E��DeDh�R�f����n��l j���ޛcG&�KN�v:�c�%�y�)õ���(��)sZ�U�:�sm%��jWX�Y���������z�NQiU�!F[C�$iu�W�!}[�\�R2�7�e��ZD%E�]m���f0�������")Z��p�D�V1��Ϟ�I��5����mnty �0�ӆ�`uiv4~m�>���P�ꆼ�4w����8��&˕Җ�p#`׃�F3�lLP'pIe�)
�xz/�O�YNJ�+OMjr�O��d7�ů�o*"R��H�,�M��Y
����N���h���\��o   �� PK     ! ��K�i  8
     word/header2.xml�V�N1}�����Bh`ł !�VQ/�x�Y�]۲����wl�&�H4��c{���ψ��uS�%ӆK���$ƈ	*.9��c:8��X"
RK�r�a__}�p�ʪB#�&[)���Z�E��k�9i8���ҞP�D�,9e�J�"J�$��Ғ2c�1Kbp׼D��	8,�n���^D�O� �"��y����O=��q�E�A��\Hu�>Bro�H�6LXc�Y�0W�4ދ�U�|-�eS�~+����D�|v���/BPS�#&�qۈC(.v�K�=q�������qŹײU;4~ڃx�b��~VW����qd�WDA64{X�ɼFP2�#����V��[��8=��)�&�$mm_�����E:>M�L��w���,I��όL�ȝ���.�n��6.�[ș����^�`�����
n�`��u����K�<3"h%�C;wӛ�8�8�*ckl]�xx�S��_�%)؎98�%��.���)��$�1��_H:ӈ�e	F�4 ��S�j��΅~]�k�*N�\�$[��� �ǫ����޺5!��V���C������--��FK����-@��Z��J�\�O� �@(�Kqw[Z�U����?G��g,�5WS^��g#��f΀���k
o����
��N�o��"�����`��7��`ߍ���'�?.z�5�U�z�x_�C�w�f�1�i�V�/>�����$W��7�'����ʙ%���G{^��ne`D���,�2��ҋ�.u�@�}�6� �+���6���9�B�,!��ڻ�m!����Xgw�{����san���gn9������   �� PK     ! :����  �     word/endnotes.xml̔�n�0�����e#�:#N�-��[�n��r,�I����Ϯ-����b}�?�IZZ_�Qut�I�9I��DBs(��������D�3]����Q8r���a�fB�p"��Z�sRyo�8v�����܂��/9��Rr�`�8�	�f��a�L�#N���K��y\�}��}l��y� k�Ȧ�G䤱:�IPp�zA�0z�s��.[���wc+j� �U��i�����9�J��Ѯ5��l-kq����/z'U��OzFGb�8G¿1G%�I=~Wi�7��6@�`��5秅��4y�F?N�p�����45w�������g7{�=Ԩ[aգ�[����Dm��0�2���,r�H:;�K|ъ��P�^}Iw�`�mmEɚڿrk���(�X�>48�2�,]M��&(f�o����3F�������k�q�^�{S�gJ��D_�|"�y�6  �� PK
       ! z���r�  r�     word/media/image1.png�PNG

   IHDR  �   �  ��   sRGB ���   gAMA  ���a   	pHYs    �&�?  �IDATx^��w�UŲ.�_o��xc��޻�{�1�s�9gE$稈�$ŀ$QA%笀A� I�$J�9ov���\s��6�-R�{�թ���g��GT�m%���J� ��'@*�O�T� ��?R����H%�	�J�������n'����T�5y�禒�T��%U���f�[E=�g�^��N�:��2�"�CaA�����F�|�����ʩj��칫��7���O�m������[U�\����$5|��m�;_5�;o�לT^��Ȗ������^%'
�[���F��Ek�����媤2�Е��*o՚�:,���/\����W����l��'�yk��D���BϨ�O����D֝��g��������$���N�y'?�7IU�������{c����fL��ȳ)̐U�B+9W��z�k�ݬ���7��p�o�°���o�	:Uh��^|�E�&S|&GTr֜����J��s��?׍�������U�u,X�?�)��`��;�B%'�V� ����vc�#�;IP���k�ȩ$���I��];��'2�6�h���T�?I�_�H>.Z�iU����3iO�C%��(w��$������9M^���r��a��Tr�,e9#L������?*��ܳ�����[^��x�� �7n��
�ݩ8|8,�F�M�x�����ly?�L;/��{�>�~L���ƫ�϶���W��x�c��G0�c��u�9oH%��g�q�]ɖ2kg�L�o]S��m?�ߡ�Gدh����f���j�g[q�Ж�J���h������p�;���=����'3��c�&�E�W�����r���P�q�D+9�Qpo!��'@*�O�T�}�T�}�T�}�T�}�T�}�T�}�T�}�T�}�T�}�T�}�#X5�*X��ͼU$ �./�Y^�+j��g~�1{}�H~��7�7le7�,�>kY���o�O�n �3g�@?�T�Jհ����-�ǡ#��YrVd�:�'�[2����=��x�Y��-����^������۟ ��Dѡ��
\f�`^l�ߨ����ykè`�	^�U��߬��2�
Śn>����w��iy���n�l�@��w�h���.m�����'|̎D����3�ͮ���5I�l��S�c����}�װ�k��%�p���e*�������&��]�F1�Zr��e|��׾{��������`��������^�|���U0^�[G�f���� ��V0^�[7A4�i�>`�yWv[�^��_�(�?#n~�w¾±�վ	�Vɤ;���;~���9z�U�?-�� �4�ڼ���>ͺz�c5e�|�'�2d��4�a/M"��u��ǐۭ[Z�Ϙ�����ΣOFzp�q��¸a���I�&��?d�+���?�3R+Gُ"�;u��,컷m��
�anݺI�W�����W�F��7� �w}D_~���g�ѡ���L��9s=�U���#N�~sh�[�xLt��Y�]�j���v�2|�`�g������?zB���;5ϕ`�(\�.��*�d��%�d�ia��ߗ/_�T0�m k�$T�a��{�������`�b�b�b�b�b�b�b�b��$u��u��)~��y���m���J/u��nndP���ȿ"/Q�n[v�!\�yQ�Z\[��]D�8���z_�F�b��U�ܕ=`��Y�a-�gc�����wa�g���`�.(]���?Q6'>>mج��ϳ=D׮]�����f�6�Ş��lؼ=���e����*m˶�>��_,���3���D�g�����wBԑ�f�};�������3�{[X�p���LY`F���T��o��|�5�q��Eo�e��u0h�:s���^"�אD޶AzN�~�B5�Ͽ���I�=Q�� -��a^{������Ŝp��T�ք���ٷ�v� +�l��62L;0Y� �%;6�_����ĳ�xܓ;@̓~�,�&Y��^ܿ���[j��Z�n��@�3z���ן���[Z��]�PDu�_6J���- ����6�1lC�)P��P�F��4�!�?��(~ȓ��[7��-#��Lڪ��m�?���9�a�>�H"�Ǧ6>'��y��@8�t�ݙL\�3䥼'*�ܙ(n�^u����C�>�l���}��D�#&���P!�g+��Y:n�o��3:�� �ϟ��#�{�, ܾ0h���S��Dx��¸�}lX�;^_�^�����b�翾t#��3���!����s���F��wA��;^-�	5�I5�nX���5�V,b����ݸq�����/���_O@h�4���0���e�v�*���)��ש�p����o�:��;an�3��cAi��w@�2�����q���v�?�W9���{�=T�y��3��i!�p�wR�|}�N���s��|EjG>�q�y��y>3������]�MX=_�t����l?��!���������Vs�;�cWtf�ؖL�d&լ׎i�#�c�tF�Œ�\�.�\���g�]L�qvW�^��s�,�W/w���e;�?M�IL v[g�c���ݹ]�~vf���$4�ӒR�_^�3�oHxy�7BܰE7��@F��{��0AH�e��$�r�~ܵ�G�8�m�1cqN��	�$hQ�o��5Z|��/��M]!F|��EJ=���a��M�P!�߬ɝxH��a��,Ķ�L] �[>���Q�u�)�f�J�T��-YA �����/�����_���3!��E����3�ax�	�S(a�ᨡ�5����u�/B�ʓ>"hr���"�p������Ryq��t6K���c8�wF���M&@� ��n�Ɇ%p��)�����	��KN!!߈� ���O��~H�/�4>]�D]u��p��%���R���S�sWQ���oN�0��;?䣧Z�.��]Ց�|ab k�J�!v�Z�����������O.|����px�l߇ܴ���Կӕ��x ¹b�$�ǟ��i�?�]X+[�'%�"��������9�p�=Z�����D6}�^!�q��ч��/|M_��2�0A��ؐ��t *sޢ������9XP��Q����~��M^����c �|��t�c;e�\�Y�r��⫕̼��ͣ΄�h2#/�s�S� ��1�������˜����?�ȇ���7��?�4����X!�.�|��o���W��b���M�L�$�;uu��9�����`�:߷n�2N����OA�������U�g��Yl8����;=���?�����^��X�2;����>�X�g}q�x䥞��b T��h�0w���Q��	�E�Y�\������������Dp�N��>d�f�����h؆��ѩa��c�� =��V����M
|I����7�n8PyOo?ab��n�ﮯP�o`JK�-p�$��+��;����:F:�|p��K]�u� 5A?ٴ���>���#AI+4���?�	� >8!��v�O�'9R�m��7���8.�}¹�6L�ql�s�H%��w�"���d�@H�^�۸�;=F��̙jD6߹�!�Ho��Y?�7%����^؎�5s�*l���v�}��al�����ru��!�bV!���N��� >"�o�|�2e/�g�!ͥ_�!�(��O���q�8��_�q��KW� ��Ui�����dM�#�;�
��d����YsS���|6���=M�n��
��O&�d���p������k��"�,&/�f��Msm�h��K`�Ɇq�C�,���8r+[�1i�j���o�J�Tv�������Gc�{��!�Z >7��Cy�Wmꋃ#��ɸ5i�Uw���9w�Ȧ��{�:a��t���qX�ܾs_�X����w��3չ� ���!I�)ۣO��Q�$�R��'�
�Ο�ɍD�0c��`<7L���9hH�!������솉{���	��o�q|3u�-v�!��u���N\�6���5��;��o��|�鱟��¦�ss����-(7��	�|��9��"D��~���Ú"f��nQ��6���D.�W"�0�@��1p6�=����߭��կ{�����q�/�q�r�2��h!8\�FWߍ1�!Ϯi��v4�!�����lق�8��FH���o���[7��k�x�F�G�k7hm�:���=4Ã���C��7�֥/}��O��Ĺu�)+��x�iX�>�޸'y���/.G!G���q`�?�c¼�o�Hd��w���ƍ8X��b����j��U��.]f�3�8\4d��إ5\�S�Iǅ-��=L��2�rw|��I��*T�.IRG��0�����S�2����h��	����њu�y��i2�� VO�9+8�6V268���&��_�mmr'r��������qX[6̝�//��Wz�%4O{Z?"�������e�g0�!|X�7����G��d��Uk��Wq���`�Lk-`����+�s�/����M�[?����������]^D����m�'�J=���1�gg�^^M�>��=�p'���8F��gϳF4�ח~ �6=������^����;�_ք \^L��êA0,�ܡK|��跂`h܍�qyB��o�����a���Bڻ�{|�nO��(�~�
p�ʍ�0�Xp��ᇟX�qލ [�00	0�t�5��o�\^�� �Io]�k8�?`����o�vy��\�fK%1���������a#>�
6C~���:,����SX,�~���[O%�����$�Y� 4,~>i���W�7�V�h�$�gm8^���#{k�Nz(���;��W�z3��x����Ȥ�F��\�v-�7�=d�X�l�@�g�]�ޞ" B��dw�^�D�߽;ϗ~@��U��� �н?3wq�R@���aV���C�њ2�)�ak:G	��)k���e%�ΓKy�A��\�n?k�Z�-�N�`�; D�Q�К~��7����7la!�MBk�` /���l3��|~/u�狇7nL���d�Fڝ�u�:Dn��4/E��ԙ�mB,����҉��ԯ{�����M�X��x����4�l`�O�8@����Ø�f`�^�M76\؝��A2�����W��vw�H]�ƶ�!w��ShG��n����ƶ�	�%��-�G�Գus�ܼ|�ՓG�����n�x^�-� ��ww
���b2�m9�+A����4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC�V¸�ѽ�р��f�X�yޢ`���ǽW�O���we�Ə@_�~�FH��+$���!��i����n�(��4��@-Y�O]�:-�{Wi8P7��c�sg�E�-{�����K�H�c��+�6�GN8�'p���u[-��S�!���kh�ݼ���W�ݩa�I�4u�ʙ��ʕϢ����Eu�R  �u���9+�����n�"7��Ia~?t�bQ|�M�h�o�|��?O�V�h�:���˫Z��#x����J��_�0��j3�x���.:�+���,���}��r�����3РQg���E�/_�D孬:uy�����9� �o��(P��eC�z����ߺ�o�@��;���a��|��kTނ58ܸI�u�'���h�t�J�s$-(�dj�
��3�w��j���U�BO���7E+�,9+��gY���~_��ӾP�/���[��;���|~$��s����x7�;m���7��M����)$0o���?g���ߗ�X�y��+@��F��5o��T�u9L�,	�rx��U/�Ҙ�TF�4��Yʪ�E���B�|��'s�
ħ�����'w�jj�gӈ:C�근q��M��S;��qV�U�鳕粹~Z��ye��\Ga�U��:iա�Dx1�����INZ�,߀�(�?��	)a��.��p������B%eK�����q���*�M�.3�@-U�̳ހZ�vH��Ο�&O_�i�d�?5�+��}~"(M�y�e
� ���%�����@Nʕ���RՏ�н?���ʒ*eF<2�\��P����J��a��9�6j9���rQ�n[v�[�������x��b*�2�4JB�͞������64%�X3��X�e	g�+�Q���!aA�ـݟi�"w>X/p��8��%��"fPzx�B�O�>����Ji����h�hy�$E0a���0D�6�����m����
ц+T��kQP�ރ��p/PBn�X�p���#_',�*�L�k��El-#(�5��*a�:��W�Qa�(]f�V�?��2��(����@>4h����@��Y\����g)���\����NJ8���[�R���_����X�Ld|�m�P�(��̯y�TP,x����.�^�z��fU�3ou�&MS�Ո�>��Ξ�::��~�� �F����Ν?�.\���ɷ�t�U¥+>��S�������O�qZ���1(Xf�T��F�l�> (��߬�h��"��p�n���#�eǰ�#�l��|�lN��E	�ف��t�]�󍡼��֝^��c�p&3�� ���i�4e�*%Le]@��j%�9��,.5o�34|,@�0���=�"
��%ai��ͯZ�Ru����)���`�0�W`q�x���:������ú
�.��B��=oUr����Nq�J�Z��~q���&����%�?�:��˘z��e	��g��[s��r)%%��ʤ��7p��U��L�*FVxU�%	g�N�z��Z���5���	�
*a���M����W	�#��(c��\��e�_~ˇ�m��?�7hD+ak-'��?��卯�k��^���t�aFUV��w��
���R��6��c�"�:j�\���C:�"L��⺀�S���f��3�*^xi��'��O�'�q��U
��=s��/_��u@t��KVy��|��5w��)z�w�S'O���OP��&�u�;v��b�'ڳw���h��f�T���uA�;���xC	�?�ӿp�<9���RKW����3ʌ:Eޓ����3��}��1��y���"_�zd�2�:hm;�M?�N�:M��a��t�"��E�"�'�b���;�9�m��U��m'/xQ��Hے�/��#a%����׮\�b�����[`�sހ�ŷ a{����!7Y4����!<�v!E�"n;���q�jH|�@ �HX	g'%|�j
J��`
J8)��n	��OJ8M���-4~�j��n���E��%յ�d���A������`8��H!\������E\��v��A�Pk0g�7���AT�)�b��r�y�KH�߃/\�q,�EX �?^x��e`�!�	�?8�O�Q��U�=����殬�抆^�,�@�0-Ǿ���Q��T5T�5x-�|�&\w��/�h*��oym2{�*\w��W�?����E���������3Y��7\e�|��cE�ߍ�u_��闽��-w%�'f�C��_�QK ��3f/��/����u̧S��	�ö�TYsT�5�/D�߾u]]�~M.Y�wlp���ŞV�S�M�y�p�m[�7�a�iL���q�1ۻ�}9��p�D���sW��QԎU��?ه�?˗�*�¥;����b~�;�"�xQͺmU�l��Qo��w�l�#��H��S�~Y�N�z~��̋Y���0O/K�W(=&������\��{𹗫�0��F�}�	�'"uJ�ʕ(>=,Jؾ�ú��+W��˗5.]f�w�"��f�R6j��?�I5��Ї���������6�(2g+�F}:M�9}F�ݰ�;��+RS�l׋b:BM�_�7��B\(�+���o����~�K2�p��M~�|��o�(J�4�5��~��6�R��.Б���qö��~}(��XR�;v����`s�Rdً"�%"}��z��a*	���-hPL�XX�x�#��E�ۥ��{*>.B��oȰO����i���:��~����/_�6����R~_��+��>sF+$�
՚���{W�M�:ߟ/O�.� g�1�0("�{����+R�����_��ӧN���Q�I�x;�&֘�q!�H�	�x`���N����h0���W`?�hd���Y��/�����X���@�����]���p��}c�u}���m7l0@>�|���vQ]�B�h���K��N�0:.��d����/� �ѝ/Dv��3�>���w�~�����s=���S7�9�O���8��C	e3o�������|ޢA�
�O��nN�`-q�q���f�>�d�?.!��I�&'^ja�pp?2��i�U�B$W4[�K6��r��no��@.j��F�jپ7�%��AY�h�K���L��#X%��7��(%([�#�Kr��V�%����բ��TO�n�M���u��Y��iY���ۃ�-Z�Y���w��������%'(�W}Vv�ƇU��|��|���%lp�JJc�g3x����'A9�����rk?�HD	CI"N��z�����|���*�%�[��{�7��3�����ݬ���N����&�ԙ@Q;4�*FGC������������O�6:��ϴc�P������0�[	'�Fd� MXn7b�WN��0�X��1��%���)5��*a����S�4�ĩA<>(�������1_�v-:,�*a�~,��	��;Zy&���O��ۓx^�Yl�E��:��p�:���Y%���/�ٰy7���IV]{ⴠD�k�n���xO8~)YW=�t+�W��$����i�m���Ȗ����\�f��#�A�p�ݔ0��˖�UK����o�oDw�K�M�����2f�t5|�D����u�:��$�s��5V�,�4�cMo�����Z�b��|�?QJ�y�w�ὤ�[� =��HP�����܈-�~d=C���a�ڴ�+��D�J��֨��H�3�
���ZEXk�٩�`U��+�6����R�J�៩O>��J��������3q��*a��v#���p�r�7�7��9J�K��^B�=��lO[�Ԇ3�d|\K�J[Od�Ћ]ތ�]�ous��a��1j
��|f���!L�4��2}��/";��}�4}Y����@�g|���\崿U�a�����W���!�R��~�F��B;��8!�K&��㌹_�
q����b�$��O�:������Wq-g���s����G�|������XeܴMO�k-���HF}�\"��S-L��\|Xx@����8������ <7n�A������%��K+((�����'rd��o��z��JGy�����/���h'I������"����n��+�.��{�4Q����tӾL���4]f
�	â�Vr�V�>-�U��:q�41�p�v �~��'�.���	���w�	�7�2�PY�[���O�S���=_#%he�0�9��v�S( �u�V�ُe��v�x����9���_'.Μ9��PR=F����#�W��T����P���x1���j%t�3g/�Y�"F�۰�������;C���s 9��蟏�v)���\��6��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC��4�(a�@ HC8J8��߷����/9馢B��)�-���i����aq�@~M�a�����Ǧ�I7�)m&�3��]�a�Z��2u䄽�����E�� �K�� D���Ɂ��������A�]71�	k�����v�i��	�c��R�M������Ä�ȁC��F.T�Y�ȱ�؉S��M��V��ʚ��ʘ��ʘ��ʚ���Q���6s�	G(@��߬W�5�r䫦2g��|�䨨����^����u��y��Нg�u��UT�y�T��ETkB��EU����W��(ӝ���%U�ܕ� w&7�T���G����ل٪q�W�wtY�M����C����V�����e8̻|���o��B%�Y˩�Y�rp^A���ࣉ*�a��=�OԢm/�-We��'����2c�BհyW
R~hW��N���0���8On=���d���?�U\7~>�L9u=�lߛ�lޓTǗތ�o��t�9n�8�x��w������ί�m܆@Q~Y(��v/�%7��8u�O&�室������qE?8x�N��a�|U	�TN��z��hJ�-��2R��G�2�U��:��$�XD���ғ��W���y�����,X��\>�♰e�j:#��8���4�\L��SB��S\�zb+�KQ9��PX������[=U�-�)k�"��m�LeT��b0t��дr篦F}2��8e!Jo����Q� ���\�U��5T�B~���ROP��\�B�@��b
��6m���$CU)^M5�ݏ��Q*�����ʂ(C�rTw����g���1d�@���q�2d-���`�x�zrxe!Ņx(7�qoҢko�n��@[$���vPy
TW���/��(3�evR�K����0` �F�^�'��=fRT>-�g)���\O�PϢ���`%k6ؐ�HIjJ"+e�z�:$:X0\,�/B�K|�߸A���$�k�^�>.�ZeG�_Ola��B����J���7ּ�t4� �J�u��������&1�������T��M��u��h��������(�����c��a�'�y���S�1��(%����p8����nڪ�z��*wR���'2�f���I���l������Q9�ܴ�
��
~�5�g�߄�s�V��O�*�yQ��^]��g��
"�ғB�����_.'�H݄)a������ɔ���v/����H3��P�H	T�I4�A��GDn��ǂ���Y4�������|`�!��n�+���}qM�T���2Z��[����lqE�'�td_�xI��t�ʑ�:.����2�ra"A�t��j1�H��M���e�z�@�J��h����Q�� X'(GV�t7h`�n�#ʘE+��9*Г��*a;0Bi�>{�f,��TS�O��`�T�GJ�2eG���:e/���:���H��^��M�䯮*�h�
�B�B��|�r��봠��?��Kg���._��K�J��D:˿��Jr��������#�� ,�!������&5U���������'O�"�9#�Ja1E?�����8��~�O�����?�)�#�&@��h��R��45Li�!@P�~�DB7���c��M����y�TL\YK���_P�z T]���N�>����d9jK��J5Z�%��zQ�j�_nRh{�o�0�p,�ԭ�Aq'A�R	M�m�Sf��D�
��n��2f2~�EɍQV ��>)��1,>(h��|Ej�G?�czf>$#+Wo��o�0���=q]/u{��*�U�y�l�[���Q�/3d��|�������0uƂh�8`EK�%4���V*V��bIY%����h�!��j�T(a랜|K���:�3�n'�b[��������p�5�C6-��fU���㼲j�~��b�,�	"���X�������ob���z?qRݺy�('���7q��V	秎+��>��Ԉ��'JD	�Oa2�X� Ѳ-�X�$Ilu�ȫ�X�a4���;[̶�P�����#}�L��}�0�ŏ�&�/"��{���|4�9Neϫgu�E	�|c���s���\�Hb�6�Y%�B�7M^k����1h�%��(a`dH�ց���=p_p-���P�(���Ǽ�D�&aǋ- /6���)*�[�c*Z�_$A�+S_�k��Α��*[�y�ݲMO����^�єq��%��?�4���F�sXKQ�e�2�a������06�7��o�7���U�jM�'��2Y���%gU�A'�]����׍�*a[� �]�aAV	w��L�w��rC�J�%#ĵ/�Q?d��"	o�p����yР�ڼ�J	S;~��4�������;��H%��&uz^KV-g��e��{gD[)�@d��_�G��a+=Ղ;TŪM�?�b�g�H�_�)��W+��M^b�E�-J��3d)�.^��Ξ;G4�0�*��G���>sV�"e�4����\�����0���Q�"�V�7�F��0�H� ��T�sė�%�����Б�����ۭ��5a�pJ��&%��J�"����P|>�˃%���S�j�m˼�zv`ƅ����*=i7��#yM�&������u'�ேT+a4.^6`Z�N��:WhE�"">�@��5,l�g��ʪ��Ҫ�̂��좪����2�
7��RA� �Jx��/:BI��z��$�չ{~��L�1#E~�3���2����"���7��]�>�N���ORpu�=y�B��s�Ҁ���YR��t�GbJ�p�:������������˅˙&g0�z1�@z>K�u�-?�(�)�Uº���Q ���n�^#��ȯ���;��ai~�pz[_D>��BX�F����#�k"UJ�KA�N���Ο��p���ߵ{��i�߹؎XW�|�2b����s�.�~>�Q� 9L��bv)P91Ad;�|P�z���ڽ�����>*g�8���7�7P����|����Q��������S���
�_�!IIIꉌ�x��:��j߬�k������F�⃓�kaJؼ��u5x�hr��.\��[���ɸ��vS�q�0N�x���IJ��e��e9�'w�~�Q�v_�]������5wV±���e��:,�Y��R/:�^����BL�J�J"��!���	�.�]�� :&G�M$���Q�����ň���+�66,nH/��7u4�6 h�g}I2ˎ4��ܼuM��]8T�Ռ}���1A����h�@�)�	�DV�YVlP�{�������.�Dn�.]�tx����4�8�D�e(���u�0�zJ��+Z�^�uW������_7�w�V)�ݣנh�ۤP�M�e)�[�,_m�%����iL䆽�x��p˖�!��.�%��r�.�+�sd����"�������C�F�.�n��f��������hm~v�Q�t�4ρ�b �(�'��poڲ=9ql_ ��������㹀�����)�u���HX	C�&���B��y��K�v������ة�q���9�sN?��g��Hq�_���1?�N�8�cǎ�Ύ���8>	?z��L�#��W.�	�E!�;z\?~R%�%�>�n�=�~1�R�9}�Lt�(��?$>>������W�?����'OQ��q�����IT'(�q0dw��B�w�7����;~���y��5ϝAt��Ѩ2�6�t�B$�y��Y��^�]��l�# oǩu~�/$~����FAe	�MΜ>�y>��|��g�R[Q^a�������Z���~c��������KS��_���bǂ����&)Xfa�]������G���]9���-�|-:�+��_�!�|Y��뜞�/�VH������ l����3������c�'7�߂:|J�Xxqc�'?�[���nz�g�n>~����#�_t�؝�gv7�b�+ �����|�~c�6�c�������8�)�O�� a%\�zSh�(.���O��[x[���@�ȒD�u8l(���
�*_���.�kh!��>!a%���L!L,�~8E%�=o���Q�o	Q���0���x	�=�(a��(�XS���Eō����I1]'oa����g�$7�ԝ���K Ql���0`����F��I4�'�[�};a||�~����ya�7�x�s��2������w�!U��!b��?�|�oJ8��Bj�0^�ܸq=�Rɾ�/m�~?tX���+��X��A�p��w@�Bqn\��ϡa	�ۯ1�O�Z��W��5�"�e`���?8���(f��8Hc3	9^��?��$��׮P*q:�;q��u��~�>�pۋ�V-���C����]��_�wf�L����F�!L��2^��]���^��0-l~!gx��[��� :�����/,L�^jC�!��k�3S �dc�~�h��� ��aH��-��&Ņ�ؗ�.�JV׮^a^X#�>�M�H�Z�'�6H�r���	��ч��Q�D/�2��aa?,l���آ4g�2
��D�v��ϴ�}���/�phz�J���5~�z�򝻲�t��D�:�Q(_hK�3;�	=Dނ�Ɍ���[hL���ʈ��%ԏ?�&�@G%�le�N��ۺ>j��b����ܒE�ߏ��0Ɩ���Z�[��/*_PIa{��gq3Y�����,*J��9� f�0ʳ����.��k���󼰄7��BY�?PR.������=ب7�>\y�k�������sn^���!Dp@&��Ǌ��g�h9r��\%��UW�@C�7V�3Q���$c�	?x�'��L�I�G���=���R^��;�2d',�7a��ϟ	Q��U�6(/�gZ`?(�
���뱅��������d!%�B��m�)a���� v�|��ZR�K�y�!0�_}��=�'��`��/���Q��D���v����#u����v�����8��>x|��C�)w�ڭ���ٺ�V�%�ۺ@��|a����y��
>��B $��S0����n{?�޺A�|w�X��s~?t��QV]����G��u�j���C��������B)29~A���P�2�����5>~A�iN����`@x���!m:���ԅ�.�|��E����]X&7n�����
��7��Y���O����d�ǇFW�b&b��F�|����ƁΘ�,�D>�e7q��φ,Gܩ3n&��p��e�N�[�l=�](�B��葝�Ir�B���k���� u\_�OO�2���N�R}���6�B�5Iq#_��l�v/��n����I��%�稣�@��Ia6n��{�������>~�Z��Dy8r�(+(|쁏h���ɴ�k�$��:��=ݚ������3������{����ԙ��\�Ƭ��\�a ����s �۹��[G�B�;:6S �0�_.���Gmp{c��u�ʛ�~]�\��s��E����}��n.(a�����xE�Αr�
�"Q%����� ��}6��sݷ[UN��y3�M'�w�p�0�]�rU]��� 	7ܜ�O7I-%� 2�r��=��m>c��#�@�դ������P��}(�//���y��YoP��>�(�����.^��7׷��
F��_@�6�6�S%G�Y0�l�D�����mp��i�,Z{�B�?Im���gEw�)�#�DV	8 ��=��g��U�����0x����)>U�{��Ign�HR3g/�҄U�`+�S�7�/����K �C	�l]�/S .��DV	�SΌ;�����h�>r��J)����:����~����k��V���)�$"k	�CSm� TZ	)a���k�ˁk���l�c0g��"J��9],%!�>�؟�������]E/C��Ҷ�z��-z�h���;��9Bx��O�*a��9F��P�Ɔ+aDM[v�0��i	Q�w��1�ú">MơFk}L&��Ip��7y�9� h�0���>k��z��B�%*P�6vN��2Y"�����a.5U}��������Z��c�������~�Gg���V$��k�}�@zX��e��)�T^/qX��[	�N:�����+8 )ЁS�0%l��.G��Q�5���={�x�Sph߰>GF|�܂/5|-����ǖ?�,^��y��U�v�o�y���}�T�T����/N܈�@�x�Z5�����TT��GZ ��W���?L3���g ��L6��o�����ip|}�;x��&�g��Z��@$J8���\�b	u�H�$��4J���w:~1@�U���WD��6Q�F��K(~&��*�I�櫒�x����]x�~A%��K�V����0�C��__"�|%R�:Gĺ�C���h`����c-G����'��)P�Q�%l���'�i0br��v�v�a�H8I��F��}�!���涂E�����
�2#��CHT	ہ`������y��� ���\�Ή�_F>���x:s�"*�c�#-~�@F�i++����lP}�~1KV~`�������Q~,����/��~��C�[��,ᶝ�P�>��>�t�1f��y�H�;�;��!�k|�9)�ɔ�_px.�W9��ai����'�J�ob&*QA+b�Y��0u(�t���|��M[�S��������C7kۓ�>��/\�2��!��d�yǲ��V�pc59F�D���]O�#�pE��ȉ���S��C[�hT�sP���4���7���o�g0'
�Y%�|��C�R�U�X�Gy�Դ�iE�2/_i���n�ڸ%k�/�h�]�qx�&/Y�߬ߤ����H�%Ʒ���%��#�_=r,���J��G8��(}Q�!�-�nJxܔy$$��3��DOh�/�� ,:2^6��Pǰ���ă�B�@��P'��V0z�a��ɛO	�P��P�������d䓉��ߢe��3!�>޿�w�[���^0��B��ZEv�[�|��(�eͭ�Y��F��1���@�)a�����X�K&_,^�ݝx�(��������dU��9�0m>�/ق�DV	���hz�ԭ�'?�p%L��2b�f�v\�B6l��n�o�l�� �L6G	{i
��t�f+86�U�]�����Cdˏ�����`7,!���������?�3D	�ķ��-G�M�ҥ��RRR��@��B�՞���3�P-����]�w%0yi�t��������5a�U��Z2�=�M�_	Gܡ��E�*aퟬ�0��S���lS�/P5H1��a���S�"���|fH5~��"����p:(=�G����M;��\Goo�Ι���߸3�_�Wr;.�-*DV	7m��Z�l��ES��S�M�f&+�)�*�w����X�x%�+	 ����N�r���iT8�UB�_論._�''o�pV���k����2y1��r�V|�$j?ہf*x��Z�/�x��D��(WG	��� �`�
�?�1��X�8z'�i=����?��y|�l�[w�b��JnP��8�,��OW������"|1c��X]���Vf��,���|J��X�,X�@��`��V4.����Xd����>�`��R�fg�ڜ����_��uY� ����9�Vɻ@>�&[����C���;��e��L�Nnw�@�֩�_�a�4��Cd-��AK��o�d!B�����A�y���q�@d����{���CG�)�p0�	�	�����@�뾰0 �UBA@�?ְJ8��3\��,w���7���t�0R��a0t�9��B���Y����4o�ӄ[?�J����� �Y~Ă��Ô���?�Pyˇ�1���J8Y�z�=W6n$Ó�˪o�6YA�S� �a|����ӭ���ځ2	��#��S�F+� �|���K�� +cX�A����VFǍ���F�[ps���
��F��@3�U���Q�7�:������a�;qx���#��#o������l% E�Ŝ���/��z4�.�G>��j���0��:q�	����e�w:�kA����ڴ%����3���*��"|�c �O�'��}U��u���.�H�g�A���:u,��cE���(��x�����:�*#�?��@]3���ع˻�*̟A������ͣ�K��s7�!������z���+Vo���D_�U��Z�ͷ:�ÛAuݭ�`�&�>*Q��z[�������Єx�o�"��w����V~\Pp�;%Q[Mb�����	�����cA^�֣飿nM�oFaba_p�%�<7%>��>�wZ��M�8���T2?�d�s���L��v ��?H$�aa��[��M1�1%����q;e�'|t>��֊�8���f9����^�y�;�z�(ҨZb׉�?�Յ���E�Ń^3��ψCn�m[�9����7ON���������"u���PT�C�叄�yw�xal���"B)�˟�G��@��@��@ �!D	AB��@ �!D	AB��@ �!D	AB��@ �!D	AB��@ �!D	AB��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!��@ �ࡄ��@ ��b�@ J�!,�@ x(!�pJ���.�K���{�q\�e���/�QdY �opat���i����PT��	"��G���w��V|�^M��%�i�i��>{��z�Z�u�������kWM$K���V�z�r(9Y]�zR�q����F������+��C+Ԏ�+կ'��������NsX�t=�e��)��O��t��Bu�u�N�-A|��{u��Q����#���~��{߾j�{c��'PQaS�x������s���������j��|?��e���o�ҍ�ׯ�;~���y�vu��9���8t��oC��~X-]�Z}��d5��Qj����G�MS+�o?I�f	qR���ȑ�j�!�vߴ�{u����6�6$��{�^n���TgN���'N�R(Ͽ�����0��g�g�9�R��T�H+��G�?��Km��m$+v�/���PN������P۶��˔@~nS�[7��v�R[����6m�N��$yS&���gY��=y����@^�c���\�/�x�{P��V�ޠ&N��� gG��!^'HG�������/��p�H�z��~����ʼ��$Ƭ��7�oS�����4���/X��}�ޭ.�>="]�e��+��@�q�vM���*^�9U��|%�?��~V�ܣ�:�3``@��[Z�~�z��۪p��*]��*c��*{�**w��*o���
��(T�s˝��ʖ�2�/��~F������_g"�f#`��p�~ݻ_|�cU�Fs�%gE��xg����UUyR^(y)Oy�������1��O@�t��ȁ�#���Y;F�W��Js�m6��j1����)5~s?��e�����z�9L��\֫�D�9GU����0�٦�*=���@����[��?F<6
H�O�>��Tl�2�\Ԩ݊&m�[��kA4��Փ�˄���(C�r*S�����q�̃�(�}�>7��;}�2�/�W�`�����I���/��o������!7����KJ7g�*:L�j����V��������\����*���#?�)�h١�J2��$�e�裱SՓ����'�>Ț���f�F���ݴ�|�2��/�/�d�x�|���-��t���J�U{����cʎѲ�װn�Cu�w�h'�0u����
^�З�=ׁ��|�1�NR�vQ��W��ka����}Wpt' ?h�.��g��8	�h��y�F����r�u�e1v�.\�F����G?��8e'��8�x�RQuD�_�������צc�뾈�&�� 1T�hp�O5��WM�����+��N�!�獡*u�L�(� S�(�#�0r����f�&=P�͛7�G�NeC<=yh�q�r���O���3���fm{��{pڔ	�'?���7��/�Du^P��޶sK�N�˩N0p��n0O��j>� �ӾW]�aV��u�g���#���z��"}ֲ�r��|��z6C�����T�u���� ��x�ߨ'��B�C�~�0�v=�qnS2��ݰ��M��������u˖#oUrC�t٬�a�.7����Ï��Gh�>�4�yXި÷�b���)@��IV/]V�5�����y�_LT1��#�td�FƔ���1��J�D�Zn��H�1)T�Z�{�}O�UD��Eu��&�������)O]Tf�� ����mե˘��pQ0�_�rEժזܘtM���C�ц쎕���&��;�F��IsL�p��@��I0�о��1�qeُrT�����?�6���Tw9H��婪�0�>4���[��;����p�z����wa_^sR9�γe���[��������5�cC�L�-�����!�����~ԑ�R Ѽ�_�|�6+@����&'��|2�5����U&�[���^5{��8����1�x���%��.,����Q����Q[f�[M�X��y�(�� E?�:sU0&,��'3�Vm^�����r�JU�x�1k�e�W@����M� �?�|��+u��&n��Oɦ^3b��0n1��ziAE��Hd������!��~O����R"~��+`!�M�O���^�'��`|.^����%V�0Ѳy� �o�56S6���p:��}o��4�)ll��'l���^ �lgC&w��@����[��f2�Â�}���T�v�t�2  c��?с�Ҵ������sZ6>��S機v��R=Y��x2Si5轏9.V��n!Z�a�
��fc����:g
3��Ξ;��Wm����VT^l���DAC8�S��o�_�lsD�N����Ȍ�55UN�{�9i�G|�RccV�è;�Jlݠo̝�������@���u߱�i�b���w���0�g�z��0�̸<1��$-+���i8E�Ż��0�.�;��\�M�^�f��V���L��'��3��Kݱ'-�@�Rm[d!�ѱ˛�zJ�(��/�����1��R���Y���QCo��/���~?���������R^�3^�ʫֳ��}��q^8_1�{��!�A eC8e�F[�j��U6`�m�>k���� �y�6��Q��6�*�l��\���Bӵ raZ0�����!M �aLҬ�)S�!���@��>�DG�W��!lÌ�֭[�} FU?[�ʼj{�N�CⲁB�=��*6T��g��v�jˏ�)[���q��BA4h�hnk[O �A?`�0�/������;���~��am�����OX�DAC8#�Q"��ݞ�ӂ(�f�3�m	�IF���b��6�¡0�d#M`l�@���0FbX�{ ��{�!�@�6r�
���g�9����M� �:�S3�R:?K�!��GM`?��v􃜔[~ e��'��'R�;6���#�y�VA���ٰy���,4@U~��:���BJ]�vF����j3�x��z�Q^5��_�\׍�W��7�¶F� �`_Ȩ�+گ��⸡l�n��S�����d�`����9"r�i��f�w64]"���D+Uo��tzM���G������Ts^i���D��ފ%��D��������oq���F"�A��aq	ژ��.]��e�qb�*K����9�`q=�D�z��F���b��_ut�
��#Pa �z�z���,O��,_��PZ�� �ˡ��K~y��߉c�a֤�s9lT�.�\CX��Rv��_���B��k�r\=����!���%�=��PZH�ib��C�
��[�NpkD�����?��67m�{�~~[��(#�U��T�!qW�ѾSR�'��!��EJ�c�{tцH3/�+������|�v���Ļ?���3��2}>���y�ĭ\�F���3������aAB�*������?s}��յ�T�%���.G�S=�V�p�(DH����0��o��`�x��j᢯9n(O�q��h61���x��#�(C�~���.X��B��`g>|���U�����)+��)$|��:%C��^�C?���4�A1�������	�)�׬�+\� /�*O���~��s`�|� p��ݝtSj�|mܸ��u��dC�e����ίs����r�Q����8�����G���a��lۓBCO�7p�+�@,� ��r�)��Q��Hu������������MrO�a(�n��*H�[Y(C����#�o�ta��}~�C��R����x0!��G�`SXi�(c���V���_��T�$����R�5�ö��2�=-[�Ve�	����x�����?4�@ Hb�����׽�p�a�S��T��$族2V�7��)A�pM>���}�&A4���	��}���{�}�~Ӡ߿����Mc
�go�w����^:�2V�Xu�̗{�R	XY�ί摾u�W�8�ǃU���{M��=�0r��EN'4}�(��A�x�gT��T�jMTEB��MU��/� {�,�����4�q����	�F�r����H3�]I��D�ÿ�lc|��X}��4_��j��~p'��Mƥ�����;~Tc�Ne�SO��1U�|U���^`k�G:zLu$C��������l�u}H��alkEF4d�ae���NnIf�{j�F���t��.t��'�&��n0�(\�!Lt��iU��i��4T���C��d�t��*[n����F)���}�hC��j��U�����Q^���u�⾭C6H7�cԆͺ�o(���
|j��W $�42����X�V�Ǥ9�	��K��*U��:q�V^ư��ۗ�ŬBމ���92-h�� ���k��i�̄	�=Q�a����C^��bD~�].�O�� ��F�?���2�Ӆ���+=0X�6xAݼq�kg���T�[�'Qˑ�5��>�Ai>깍�q� �(��~(�z�����y�}�[X-��c��r���4�:}V5n݃t�%�6nz�?g>u�D��&�U�j�_�#?�ge+5T'N��h�G=c��C�@��e�S��aG}a�/���ir���mQ\C���I�;v�d��pDym��!Lt���N�悺�d���n����%;��֔���7���y��m�ƌղ��lZwoOd?
D@8]�M[PEhBme�ĭ`	���3���	���z�:-:{�*�i �f��Jm޼��߰a�?e����[|��]����-��!)=��棟�>D�a�6n�����c����{g�\H�kρ\��qH���۫S��i~�]-�=Y�px����z���b��O�!���լ"l��˓'p��W��q~��rO@�ሱ���6|Qu�5���C��o�!�@��&X��s�j��#F����e����.o�!�mA��A�.*���cԔ�=�+�W+�h�7�����hh�5?/���a�[��[s�u�:
��ٌ��x�\�Y$϶�>�x�z"c)��,0��j�k��Tcూ�� ��b��,�I�Z^}�x��{�����3�q��>�`ͺ����IT�S��3[ �!��mp֭]`\���Ο�ēh���͇I����iܲ;�q�diC8������նKP�;��{�����À"�k;a�=�D�F�#y/cV�u��3�#�"�)��!��*Iݸq�&�#[0�P��901cC�Ęc��=���r�-Q�+�&�ׇ��|6����y7�0&,Uk�P���V����M�wU����ra�7y��A�~��:�"���|��%�}1��a1Xb��\�f�K0B2�0��y�z��n�,zp��o��j���N��ii�5����F|4��|�W(��nx)qy�)��w����d�*x��)���1V�4ݸuE����j>�@�Q{'h;�n���lDa�����Ɋ�w�&/!C�? ڨ��"�@�Co�Z��ݞo��&hXMjѮh�8pP�I_v@������sgu�8��k@�C���S0|���h��Y>�1%��5�צ(W�����L>��6}�o���/�#߰/u��o��F("_���_�0Q���{�/ j�׸/MT`Y>�9�&L6dP�n�2�Q�m0�.9�S}�毪�Z�1��C�/��FU���z�:������q���=�[Jl�O�� �o�}�K�~��}2�G|�������M	(>�7h|�S#C��2՜�o+M�@iᘾF4��[SP^L(��Q�m�	�����qH�e����zvޗ�)��!ܡB���0���M�� ��1b» m�Nغ����§'i�Z���j���_ ��gE��

n\iC/e W����BOtPI	�h����-�M	Q:)���ǋ�w��Myp�
�΁���ԫ�z�`H;%�
ѡ3���悆mj�#�Z�,�V�3��t�z��X�*R��*Z�^B�a�������Q��|Xy�p� ���4l�U]��WL|� �������z0���~
~��(.X�i����e/Y�F,V����a�3.���@���,\>����	.���0�]���t�:rL#c������9�x����B%�q�~6q�:}��o��B�8��%�pZ�xp���������~��jԲ;��E��ů����G�-X�\����|y�e>r
�C�y�>o\��-�HV��$�`��=�U�(�W��j�m�X�g�87�/>�5�aq,X����>Ǘ�A!���-w��� 2l,�u(������'�O|b�e�v��M�&ۤP����[��>y���6$�u︵����{�c��V�e���f�>^L5��:��@�����4Y/BFzPT�b��U�i2ֶӫ��q3�A�A�ߠw��b�16ӿ`�a�ƅU DPH�3A�x�ۊg���i&��� �j�S`E�N�x�
:��r�ܕ�qd�j9����#ƥ�
�O6ں
w	\�a���&
$+��:�(�����9���ލr!�B�[��	��1�����Q|C`'d�����1��"�1�#Sϡ�]��P>�=�O8�0�m��!�i?���+�9G;�����5߻�o���������rF���:涄{�X�qco@�9O~b��c!���{U����{n�\�
���|f.QH�	���{xoVz��JX��QQ-\��Y�q`��v}��=�'��(�:c%(a%%]SW4W��7pS�V�����n�_�3��)�@�7�}0����՚$vW���wU�d=ރ�V"��#o5�����34����W��}�ai�x�Z���j�w�ԝ��u��X�U��Y(ԸM�ʩvsJ�VWo�p\�@ ��{ng'C�R����+�7,ф@t��ê �a��$
�p*oU2��0�дQ�~�C�ʄ}i����^�M��u��0��ܒ�'����@�7��3��zT��D� bco�q��OCX����8��T�m��/�}{�O�����=|�F�e>)����D�D:ae#�\v�I]�/�sh�Oi�����b�=;��u�a�&
��>M}P5R���g�_< m���H�d'�:CZ�O��t�R[S~��3��T���{�ߖ%;��@xJ��5�e��}{c��Y6RK��m䦋6D��_�OQ��>\��T����D�m&^������$J��'�S�':/�ܨ��I%8-����(��k�^�K��o\�BX+K�yI0��2k���AX�X@�,Ú�I;�r"��?���k���vy�:���gnO��O��N��Tx����C85 C�.@�`�
>3_�?�l�Ў�.Ù��X�
L+@K۶���oI��Jy
�Re+7R�Z��s�O���h ����ht�_�~U}��Jչ��|�C��O��\�k�"���S�0RmܢoncBR��,8!���J���~��L��!���Uk6���n�jף��:�^��w?���x>�|Z�a�z��a|��-A�s嫮�����l�����|�V����蠺J(�Hyw��Ge�YIuy�??����Sg^]P�/�JO���.�V@�'1eǂ�=w^�{���Q���C�W����v��7Q�FHJy�e �~�3v�jҲ;ߒ�� ��o���U�ƝY���37ׁ�x�p��ϻv�:�;�Z�ڄ�-ݿ�k��j֦�0�#�l�:u�y�
��[�O'���
YO/ݿ'O�Ql����A�}�*W'~��l���1��6$ȝ���`,���϶���-���q.�q�m����Y��n�����������2��&Y}�|��V�%���ڪ�(���:�r�椋j�.��z�h�gU��:���H	T�y_,�2��ᨓ��^V��Np��%�o�IK}JM��@�����"�3���m��ʐ�����~�2;]�4�E��v*���>CԵk��)LG���6�S=]�=�L��*Ԯ���~���Y����[4�Ta��w��a�8o.߿;dkDj@$[#�D����>G��'F�|Rvp��-�x��|�F^ �Y�����{�\��lO�3|+��KAAQ��?b��%�+���_�58O�K�#cq��y\������cqF*��{k�u�6���Q��;�|�6��a|Q�k����Ekq���4^]��"s�
|�ڨO�1� �PP~x���2�!'�`�q�n�j���u�W�:v��*AF&�E�1��V�e����l}��}�����L�U.�=�Lبzr���!\n�|�.��pC�S������fҊnW�c�h�Z�q|��1��e�#/��k�멩����ڹk���A���S|�>���Sy���	�������7a�rϱ|P��8S��77F�'%���Um���$�)������>݇��Ml���� �Q5��1|�=te$��2���G�Y���Mǅi�hr�9Q[���t�0I>�����hc��f]��{����UǑAkD�P��v��xG�Z�#� ьY�^R��軥+6R'N�a�x�G�`]L�2֥G�t���c�R~�?k�/zݜ��Gt�&C5j����1@>'{7�:|���ԀHV��DAC�w���B�2)�J4�����c!&�l��a�zF�HU�HO��A�t��yp���u���p���|��[�pN�]-���N��_�)5u��IRd0J��D:9I���K�!V���ߌYȀ���U�C�w��))��}�Q7x��B��c^���2�����Y���?�9��73���ʱ����>����k}�UƘ� M�R�0X���7��Y�=_x�41�?]����W`��!p�Ap�!n�C\贮������@�ÔٞT���d���t�L�7�5i�
ޑ�Ij��#h�盽��ײ]oU�Jc2��s�B�PO8�:���D@�p�
�k�y)J�A嚭���j˓�Fy�/8r���e.��m������_Nۼ�����E�J��#����3{ɑ��Lz����0�U�c��`H�g&t��3�����s;�[$1��/�4_Ŏ���7"��ۈ��G��o�'�^��R����R-�1ڍ+�������2�\ǂ-������ނ��"�)�eu��O�����"4��;��!��U��/�2@_0e�مGU��RU�6E��F�-� ����!��O�~e��l(.��u{�gh�����/���`G��>�9��[p��H���`��n�n��zj�v�^%��/���ёM",&D±n�TXLH�7%+6TM�؊�Q�'/MzKQ��f��k4W7m��7�©��w��!�>�^��x`$�쀰~�^��
�B����v���?M��L�h��?������ޯ覥��k�t�K�Z�P�~ӴMu��qF�7n��(L�����c����|a��o��;�UW��LjDC�u~Se�ܦ>-�F�#��e�r�֮
U�����Y�F}��F/�}���Z�Ɍ���)oo}���4���}���V�z3u���m� ��_�_����b�:u�4��tb��Na��Μ=��[#GV��L��w�lZ:Ϡ?Q_-[M�� &�@:w��!Y��.�	�e+�Uy��Po6V�0���F$QhZZN]C�Hf���Wm`��Dq��\~�'[�C�]����w�k�}a�6 Pd����+3��Z.�O��a�vs��\C@�jk|B�!�q-�{g�ƪ8�^�I�~�ok2���0�B��m�7&���P�G��p�h�ӕLa�i�Lso ��5����U���5�ʓF����}���P>�]z`���}�z�]ͷq!�m;���)�+"����vИ��F�����0`����tQ��EE^وRc�� ����R3����Q�@�D��&?Q�ē�)dkDj@$[#�DAC8s�J����Ԧ�;�w�mS�� ��@����;y�B(?V���gUE2���f.Qiݾ7�	����V���W���(��_�A��,"]~�G��c��e�|b�|�F����UM��Zv�9����sM��Qfx�p�
���
T�cǎ��e�e|�O����續�j-_���]�A�a�w�3ሆV��%���.@оxMn_m�N�*�:j���H<6ƨͰ��)4]"�0�Sg�|q2������eN�(�OQ�!�ʫf�d��b5mЌ&v�CVN��$�~���!#,�n�4h�F��$7��n�F_���M꧟wSt��dJ�i���϶V�p���V�?h	M(0	�r����TV�).S(��!��K/u{[��v_6R�}�Sݸq��$�/@t�a��+�r=c��>V|7oѫy��PH\���л�I���U�=�z��G��s�F9��ÞU?�7ڥc�7�/�
�]ߐt������U{}��6�܀F����f����;5ފv��CΗ^DAC����1ڟ�����:M���a�gd�g�RFU��F�~8��2jl*V��`�i��e������c@CǌBa��q#�!+W}KFV�~������T���~I�Sޭ�����[�ُ�`AݺyC=U�md��{*�Y�-0L�AC��}��AF,f��P֪�F�:}V}0j��@�kc�J�g���J��w��@�x���ң�;�S"|p���x�2��^��lؕsՑ��`�:귃�	�Y�l���u:����v�=��r����Ԯ�N�>��Tn̓�>V�>��g�1A�� J�!���J�#˨�S��(/����/�e���n� b�od˻���� �6dS�P���p��y���O��.�0�D������^߂�g$�v���؏E�q�z�0ר�U�Ղe��De�D�Z�[0�i�!݃��@��hՓR�1	�I�����R?������7�����Ue=!3�>�[?$�+�zK������D�(h[��?��79�=�DAC+�0����Dޠ鷌x�&쫞8�߄E�{1�S"1��DAC�F,J����j���c�h���Z��f�;tn��_(̅_}����R	�G�7����K�ُ�x��1�/^��*R��{i�)j(���$�nF��d2���y�*A�^{���h#.'ə t���0�J}eK'{�J|��5����c����r�;��"����aX��G�E��1���>Cq��{R�P\���l�ʍ�`��1@t'��ٳgUn��^j�ɛ�S��x�A�C�W،��Z�A�ʙ>����=���{�3�Q���շ	08�ф�ǟvs�(�w�y�����u0������~�0�iR��x�"�!L|��`�54�d|�����L��?�=1��Ɵk�p�������f���	/������/+����[�?*�����}��@�S�����7~��������>�ycF����۰���|̉>y��ջ���x�Ca���>��*M���,�}�l� ���������-�&��0�� 
��������ࡣ��2�������)�&V�Hm/����5"5 ��w��=���,b��`�"\�~]�y�ul��A�K�U��!�A��,��Ym��'n7m$ie�>ky5f�T���O�)m�V^�^9#>V�j�R����2�i�[�j�ΟU�� we$���0�IV�p�X�澭&����P��ʵ�����V�aHae{=�b�{�&���I��W�ݨ��8A]m6�ُ	�X�/H�x�ín�N�gлqY-�̔�L��-�R�5B���-(��	+���+c��`\S�P��Q�!�'�!l�׾����e'~���eh�2�F�����_lү����P�~4a�\} �)��� 
~,]5�3Vc�9e%�~����-z��W+�0�?�8����|��� �mj��-���̺:�[+��x����0V{�����_�f�����/�-���n ���t�ʃq��pl=X�t%�?���^����[è>�òM�Q�|������ǂ�����rh�C�q{�۴��R�a�w������?��	����A�!|���eYN�!��~OM���I`�vx&����_�c�
L��i5h�E��^u
���?��ͻ�F�^V'N��*bKi�=��fW��!��ׯ�HYb� #�G���r�OG�W��5��c� ^7���^�)��?����J���W��ۮ�8 �ȍ�,�v���W"�J��E��A">9~2�c��4��l�L>�+3��4��j�c�@��UD7hBS�nX�N~��ǎ��~����sO�yCݢ���J�^�-�߮hB0X�bN��R�"�eIR�H^�@�m�ܐ��d�ԁ�Vzg���;|}�xO���D�ߠW���
DAC���M3���CG�]ߊ0��Y�]|������ߚƸc"���Ս=&�B��V lK��NN2���>���K�6/-��!���#G�g�؄�ƴ��M�&N����Y~��rWa=8e���uc�:�6~��;� b#Z�*�&�A�2�y��7�Q�TO:��rWQ�hӃ�v�W�֐�����0�9�m>pH��w�~��p��I��xKF},Gz+r�t
�B��3�)�/,V�q�b�ݳ� ���x�u�1���W�q ������ي0\
K+!�����>a�S�!\��ڻ/���!���%T�E��ԭ�+�X��cET��8>i� _���P7n�P-���
\Ł�0�BŒ1ky���������ڼ�.]&�5�}�W���Ga�ȱ	�G�8�a�>��&b�p�}F��⤇����'aC|����x�*+)?��x	� �{��E^i�+��.5>���`�	�u�B�u��;p��N�(�����U3�@{���*b�'�|��Iح%X�j/�P649�J�8yR����;� {���$��b�6����2��x�z����(ʦ�/"ڨ'ـ�Lu�K6~#���V*A4����m7��&/N�qL��J��c&1��o #�Q[#P.*�����?�]H���5�x��N�7���`�6��bNxb�(h���UC�n���U�j������0��([A��?�U����^�3��y8�p��C���i� `]d����6wi�SgZ���]s"f����hOm���&�/dr�GV�tyW��ȓ+;�E��K���l?�v�f*���0��6z󪳧#� an��À���4)�#��!�����~�(o�¹͐�C���[��}0V=��w n(Zj�F"!z��K�K�Լ�	�����|�Ƽ�c�ĳ���(�~��'���z����NF��?u
+k�F,�"�r����j<=�g�v�_���忉 a;�+���,��}ݔ�����D��b�9�^b �T�F�9>So�c{���+W���L��]���	0^j����m���M�9ր��@�����z�^;V����Dj�aņ8����ǀQ�y�;V����7�g�넔hֲj�$B��I���
Ф�b`f�1�c���}Ko�8~�j��V⼪M���r��� ������cO������Q�?l�c5n�]ٳ�N�9��Vi�+��S׺�1��_�?����7y�/�+=�_,4{F��C�}Ǐ�͆0�����9��NG9��1�Ǟi�Q�����Q�\N��
D_.���)�e��ˬ��=�h;�/S���o�
�I�!I�n��5������B.�HD�=��O_��cX$�ɓ�'�-����Y�r#u��>�*�f�N�0�z�y����-x�،�8�F�6��0!u?�u��C�wd7����_�ڏ'�O�2M��KT�J"{�.M�1i_�[?6m5G5�� 3�	3���$h����=D��6e~Xx*��l�LȽ�N��3�L}���\�B��[� _�4��Ѿ��~(:C�/�(n��=�׻P&,N �7�aJu��[�l��D���}H��0|ȃח�����^�*L&�F�){LIԫ�;��q���_�)��E������-��i������:z �}��/ۿX���#O�y�
�/Xq$���Փ]�p��p�K�z�\�v�|���|�.A��?O��7O9���M箠Wq��dj��	��Ƹ��y�A2��Y�4�����'�&cr�jIFS�6=nGz�X�t�:u�=n��Vfa�7��z�� J��j޾����{��q3����t�n'�0^!`���>|TM�>��g�:w�,��������;T�|E�[O}������=��o"lز�|z�:D�h�G5o�[u�5�/1���"�)cm�'k�ݪ�O�>Em>�dd.b��ݷ��Aaq�N�6ʜM�-k�W����6~���/{؏u���7�⣩&L��u�뷿ݸUǉ
o�C��̹_���>�	Ec���/�Uo��̹K�᣸qK�֛�L+P'�ΟS3(m���F�oAO�?�����	��{�38ߔt�n�D��"
?_���>��;�����3ܜ�q����N�>c��Z�e�J�GF�w8�,��p1������v�@��g�o��������y�gKW��k�;wﯚ���+��_W}6~���',
i�����������P?(��yK�|o.'�Ȑx���ׯ]U�H��Q��U�#ojK�NF{'�ED�[��/]�K�pn�Oc�: ��7Χ��E�:s�,���Oa�S��f#�Q��i�vK�:u�x�V2��>y��q�p��� �I�6=����\�)�E���(�l�P=Ϟ��\?g��w��a����uKZ	FȘG"�V`�`�o�FH� 8�>�*?:�w��7�x�������g����C�Ɓ�a��)��"�?l}%�7[\L�l<6�44O��xŃ��k�æ��p3��O��}\7]�^��am9�����i��^=�xD�ˇz�
o�,�N?�f;aL��3*����#a"i%V^�o\����8?(oX�؈�#�q#u�ڸ�|:ʨ��7eD� 7���¤._|l�W���ڰ:?+k�G�� ^!}��W+��qy���m7�����S�[��a"�<	�£=�����SiiY�<8�6~ \��@ ��@ CX �@�PBa�@ �C	1��@ %��@ CX �@�PBa�@ �C	1��@ %��@ CX �@����!��%�#`    IEND�B`�PK     ! �R%�#  �     word/theme/theme1.xml�YM�7������c�7�c;i����&%GyF�Q�I�]%9
�i顁�z(m	����mS����xlɖY�l`)Y�Z�����J�4��WN�㘦�z�� �4�i�q�K-p����3Gܹ����ᎈQ���O��8�ӝr���Kt�R�7�,�BVYTR�U*�rq�&����f.��������YC@�A�
N���s�0pIǑ����ȅ��8��w/��FDl����oa�0'5eǢ���u=��]�W "6q��1h,�) 9Ӝ���z�^�[`5P^���7�������7�]/�xʋ�~8�W1�@yѳĤY�]�@y���oV�}�i�(&8�l�+^���]BƔ\��۞;l�������>��Z�S6� �\(p
�|��0�8��(�o
S�es�VV���qUIE� �Y�M�h�� 0�c��� o^����sp����_N?>}����L#����_���S����^?�ʎ�:���>���/�@�_}���^}���?�t�!N7�1�M91� h����a�n�M#S��X��sH��Cf�2)6���}��A�f[���� �SJz�Y�t=K��,�샳����ml-���T�wls��Ƞy�Ȕ��H���N����؈�>�t,�=z[Cr�G�jZ]É���FP�ۈ��]У�澏�L����\"b��*�	�XÄ��=(bɃ9��s!3!B� D��ln��A���{���<1�L���)Ց}:�c�L��q�؏�D.QnQa%A���e`�5�w12�}�޾#�վ@���m	D��8'c����'8=S��d�{��.��շO��{!�˰uG���6ܺx�����kw��[Hn��t�����to���/�+�V��⪮�$[��cLȁ��Ǖ�s9�p(UE-��,.�3p���`�p*���"�pq0�\����;� �d��yk�Z(V��|)��i$��Fs��t�j�zT.d����6�I�n!�,� �fv.,����V�k��� �~��ܜ�\o��0�Sn_d��3�-��k��3��i����L�2�a�֛�9��UJzY(6i4[�"י��iI�8�{��I7�v����b2��x���Di�	�"��EY���>�qS]��,'r��i �[����xAɵ+/r�KO2�Q �����/wb�}KpV�3I� �����m(�5�Y C��2�!f��^EqM�[���l�E!��pq��b��UyIG��b�>+����(ʒ�֧��FY�&�[��Դ�ǻ;�5V+�7X�ҽ�u�B붝o h�V��2�j�V��9^��Ks�qާ������^�j�&��\�}y]��Ut"���G�\	Tk�.'��8*^��k�_���Aɭ��R���K]ϫW^����ʠ�8�z��C�4)Su.+c���Z���`��ڰ]o��v�;,��^����R��7�þ��Ç8R`�[��ƠUjT}��6*�V��tk����n��"�r��w^�k�   �� PK     ! �T0�  �     word/settings.xml�Xݒ�6�ߪ}�._�ǒ���'6��ޤƝ�A��D	ܞ�־����ݧS�����t�t�#!}��[]�ו��]�dqc��e��]�z�-��M��Еm����t�>��O���=�n�Dӭ��vq��v�Zu��Ժ�`[� ����=��������.s[��/�eU�O+F��8�����k�g˺̝��T�v�+ss��5�{�N*�͏�i���ʙ
b�Mw(�n�V�Yk f#����c]��N��#ݓu�w���7(����@u5X6�����?��s��)P�d|z��cؕ��zO&���:�&��Ө���}c��V�JH�"Z|Z�fm}sZ���P�4!�� ���ݦ׽�kMU�$�+���i�w�zΒQ�Uw������k~��f5�1���h�*t���ͷ>++3�:��G���0�%�Օ��������v��v+�9���3n��rQ�靭�q����4�L��m�5�d���Ѯ�Ap����-�Z�]09��6N띵}c{�{���Ŝ�+���Z�4ū�+;/������ry�LK�4���X~�la��]�~J
�,�b��,,��,����M�T���)3QS�t��,���_���0���g謁������79�Ue{W:g�禀N�ۜ���qࠄ��&�Ξ�y���b�ſ�w��F�?#Ӈ����y(!�2L��!�z^�#�E��e�#2��οB|�%�������N$��#P,��$�x>���Z&y�ce2�ϵ�B|�5�x��[�
I�8�d4������t@R��$�Ш�x�LP��~�2�r,�=�k��T�5>o�WHZ�(���D�!:ל1��Qs���H�b��?\���U�R�e/I��*�P$���2A���6�'�4�(�q��|�1C�@@��(ED#���Y�[S2hl"aAy RJ#t�DFe���gR�hԾ��?� _C|�	�F�Wh�����3_C|%��@r�9��) �@� ��GAo�~���ħ�4 �p�O (��U9�C9����9@���bJ�����r�%(���Ð0�Zc*�(��Q_H�r|"�	���L�se�14����8��C��Y���q,E�r'N��룈$
����c��(&3|7�m)Vh�
�s�Ʀ�:ZS%y��QK��xl�/�-�B��VlA(�P�NO	�#i�MbF�z�Ărܚ�Ñԋ�o�$���$��%���P?��=eb*y��NC�߉iAg'��"8�h�q�	�.(��ėʪ4�>װ5�ѧo�$2�C�PD/F��|�\Ǉ*�H>�Q$䌣}�Ep�@ٛeܛ����	�^�d�)}z��7���t�u���n�VÈ�{��fƷfg�x�2#��v��	�j]U����D��Eٵ�ٍ�՝v�����J��黭�Fɸ;{l'��t;s�!�Z'�l�/e=˻�v3k5�==��M����2=�u��������X�,�L��Wn3i͝n��d����EU�=�=��=�/�=;cl�؄�/:2��燋�Ͳg�Y�]d|��L�2q����d��ָ�l��>?�*{2ŏ��h�����O_g��W����lݾ41����/�G�_3\��%�q�To/�r�ȫ��7��N���ؿF���n��?@e��]�;S���柋�s��oD� ��.i@�%O�ZF	�D�"��u����6�/�?�  �� PK     ! !���f  �   ( customXml/itemProps2.xml �$ (�                                  �SQO�0~7�?,}��!$�	�&F1�t7h\ۥ������/	���k�����:��"x��)�#F��dR�R򸘅=8�:�ѐm�hx~6�\?��s����|����;���2֛��v��˘�äӝv�b6�ͦ$���ø���>�N�Aq���̍U}hW��01�R���K���z�����ݰ�VY�Ǣ��ƙ#a��X�;*�FO�x+��?C-�oТ��ƈV.+w�c��D����ӧۛ�����;���J.��j�M���ee�-
���h��'�V�����~�V�e�+���M�q]�ѥwܢ{�w˚���~[�:��^�O   �� PK     ! Lr_�     ( customXml/item2.xml �$ (�                                  �Y[o�8~_i�C�}.�R��JG��+U��T��j�F�퀷�����~��!@m����}�~|ho?���{�R1��~���=ʱ �ϧ~������-�,��\��S��4Al�������g��7�Щ��bɽ��Y'�9j^}�M��ۃ����ߥj��Ɍ*,Y��i����ۅuVʐ�0E���O!�F�G!����;��`=�Z�� P�X�I�B�Hw�HEӠ�펂�jD�FAM~I� �T��R3��޽֒���ʿ���ە"����HΩ6�V)´�,�,)خe�G)b4&ʸ.�ѧ�^��FQ�z��O��(Gh\Z�Uj,���r�rn�����湳�|�ݴ�u��hLm&r��{. Yӕ	c�n�3������H�'���|ą�80�{��^A^���OY��.�
Ύ�L�V6p����tI��S���3�,�$����A�Ceo]�x�J�V�^*A-�2��|Ÿ�BT��@i&c!8(���^�l�j*���u�=�n
H�#E��I��@��JB��B�ɺ�t��
��[ Hƌ�Z\�D ���'��_A�:�����}��'kQ|	�k[���5T�Z���keޔ*i�O��H	���gR�۪\�vU.�֨��T�ÄX��;S��i�G�x�M�}���ܾ'��*s�T�u>)L$�y�.^���h��#�lv�Z�Az���R��\M63�����z)$1/�9�>�N���wH���붺�l�Lv2Iߙ[U��m�L�S>��w��u�����z�_̸Hyz�!KB*=y
�Þ�^��� �z(Mc�H$�D8caL=xؼ,���J���=��"���-�V���6g�]��H�'�zS2��ȝ�7�SU}�j5s3��y���3��SiZ��EƧbF>6����y���g;3pc��N�Of��܈�	�v���1׏ʹ:��q�A�ec2ߓB��nڲ��Ҫ;��u疞�2{�WJ`fƐ�a��k�pW�p��3��2�h `Y�K%#Pm�R�;w2�e�4M�OgAK�Bs>�;)�6�y����a�4�{|���tՉ4;Y�2wsx���s�N��FT��LČ���~���]��/����Ь�D���y0��T&���~���x�~53�s��#LM�y��R�����>:O]�H��*�w�  �� PK     ! cR���   O   ( customXml/itemProps1.xml �$ (�                                  d�Ak�@���ٻ�Il�A#�ZZ�uYǸ����ZJ�{WzJÛa�����a����Jl�TD�4��]+���Ņ����Մ*�P��C�ӡW���Å�Fa`B����J�]wκǸ��&Ί,�O�6����4yv
��-��v��*12�)I�`%8���U��J��E�Xp,wi�$����N�^��^��@�r��x�b��H8p��J��M0���Fǁß3�5	Y��d�wO�   �� PK     ! t?9z�   (   customXml/_rels/item1.xml.rels �(�                                                                                                                                                                                                                                                                 �ϱ��0�����ho��P��K)t;J�GILc�Xji߾�+t�(���Q���E]1��h��jP>N~��j����.�����G{��J	����D60��o���,W�0��H9X)c�t��l'�_u����ݓ���|P�=�;6��w�#w	�E�v
���d*���yB1��ߪ��	�k���  �� PK     ! \�'"�   (   customXml/_rels/item2.xml.rels �(�                                                                                                                                                                                                                                                                 �����0�����nS=�,M�,�7�.x��dBf}{����g��-�ꊙ=E����Q��h��/��Xl��Lܑa�.���VJ�'�X%��I$}k�n�`����\��J�uvD�����h_Lu��C���~b�0x�?�.������B��c�Ҩ:�G^0�� PK     ! {���   (   customXml/_rels/item3.xml.rels �(�                                                                                                                                                                                                                                                                 �����0�����nSY�zYo"]��i�Ʉ�(���=������?��naVW��)XU5(��zG?�~��bcog�h���v�ќp�RB�%��2PVʘG����#�u]��߀��T��@>�+P�=�;6�w�M�0ʋ
�.,�a>f*���yD1���jSt����   �� PK     ! ���   (   customXml/_rels/item4.xml.rels �(�                                                                                                                                                                                                                                                                 �����0�����nSEY�zYo"]��i�Ʉ�(���=������?��naVW��)XU5(��zG?�~��bcog�h���v�ќp�RB�%��2PVʘG����#�u]��߀��T��@>�+P�=�;6�w�M�0ʋ
�.,�a>f*���yD1���jSt����   �� PK     ! �@(��  �   docProps/app.xml �(�                                                                                                                                                                                                                                                                 �S�n�0��?�7��tkEŐt�a[�mϪL;�dI�Ԡ�׏���z�N|$��DR�����|P֬H1�IF�Z�vE��W$Q�Zhk`E��5���m�uࣂ�!�	+���-)r�3�4�w""�-�M�$l�|��DZ��
/L��	�����J75���U6
]�xQ.00B�-^�{���\,JF���������_^1:�o�i%E���Jzl��^q���0|��W�ȱ���$5s�=��ϋ��|ދ!�I�a�-���}s�[i�[���C\@F볠���K�=� �q+r^	ɐ6���.D�+5r��7�iS[�y�'�q�؃^����
����w�S���A�D�T٩�?�k�9a�|ss����������Uv��䵏����U�8\��4����P�d�Ɍv���:U������� ����myq9����t��:����  �� PK     ! ��b#�   �    ( customXml/item1.xml �$ (�                                  l�=�0�᫠��2�R�S/B�F��(6?�=)���c���#��>�P���8��)�V�l^4G94�j���Q᱃oMk�ڒ�`�����ݩ�9\��e�B�!oA�O>��\��7o   �� PK     ! _I -  =     word/fontTable.xmlĔ�n�0��O�=X�_ℏR�P+Ҥ�����q��?"ېq�;q��Pɤv�%�9~sΣ�?�T��u���=��̬�ޤ����f���T��4����~�~�p_N2��C�_��b)ν/&Q�X�u=Sp��XE=��M����fTA�X	)�!J���^�b�L0�ɰ��ڇ����v�(\�V^�V�.�a�9�Y��OQ��6���H	f�3��A3ME�
��$v3H��M>o��t%>T��O���h� ��R����j�x�=�)&	Y�!ܫ5 �ꎣ*���:^�ԉ��3���孾�VTE�!'6عI�#�+Y.q��)�0[���V��F�R),��wa>��fT8#�,w艗�QT_ �����L�|�If/�,@���OD�^'R�\OdeI4��m/И������7��Pp2�=�x��o4Z�2�u>��F�C���?��T��c*��la��W�F��
�R��On�?O��au%��
���	j�Z�Elr�ĭ���:qg���'nBn������yp�_   �� PK     ! �C��   "   ( customXml/item3.xml �$ (�                                  ��?k�@��bn��i�-�v��	�tg�}����R��.�7v��>?�o�ҼQ�$dJ�jq��c_�R�P�D�|�]�bV: eT�S���� 1�@p׶���pBC�U�s�����׃�:o�^ϧ�O{�X9�wU���G)h��=�3Vc�O�V�n�'	�Llgd�i�`����;   �� PK     ! ���	]  @   ( customXml/itemProps3.xml �$ (�                                  �R]k�0}�?���i�6�XE,�0a�|魆5IIn���_Z�@Na7�|����MU�+X'���b���z���y���!�����hC&��Q�G��XX ��?H/�|��~�',	����4���4���8�'q|��Oxi�i\F6���R'6���L�,�U�h�Ԕ���(�H{����˫��ȸ��C?B���Zc��v���IǺZ�S6�Ts��=�[u�B��$��@�}�RRX�L��0ji��[r���El��%v�ꀎ����%�ۊim}�en�rg���q�Ƌ�Gf�߷�|G'cJ]��㦕��nQ����T3=ڪv>���   �� PK     ! 5eX�   �    ( customXml/item4.xml �$ (�                                  ��M
�0��}�w9��.\�
B��B��n�8�@~$Ao� �'�r�^�F�,(���a�����s��&�&�q����[�ؓ���2Ζ�ĔaK+Jvg}�eK5�Z3��'RV�y�Ct���=�́Gv+ˊI#�	K�>�������   �� PK     ! ����   U   ( customXml/itemProps4.xml �$ (�                                  ���j�0���ݵc�-+qJ�S�ul���8�!��픎�w��N�q'�IHߏ���N�C4�q(6�v�w���N��t������}��Pwq��$c�A���(7L�g�ዲC�\���8�-;���(Z\T�RPֲmU|�j��DcJ󎐨Fme��Y��}o�^-V�D�OD-Yo?�͚�w�U���hK0��\�e2~r?�45��Z���   �� PK     ! 0"���  U�     word/styles.xml�[sۺ��;����S��غX�=�9c)v���DN����c�PI*�����Dj	�n ��]����?V���'i(�^��q��/�0~��}}�~�����_�^x����_����y��DKߊ5��΅HV,�?�ǣK�6�7�X�Y��(�^�����$m(b�}�A���3-��HE�.�uZО�ОE���4�'��rފ����*���E�V���FI����o� '8�`X��7��H��@���m�,U?����4���kg��|�R?d��
%��e��=���4�LCV�s�����Yi�$�ޑj1�����E����2U=�l�X�Xl�񛯳rOJ��{�cɛ٥<2'��-��z��nx��P�����+h*C��?�l�زM&L#���b���K���7˽@��[�?�`��=ݖ����>	E"-��w�۔g|~��ǥ�e�oKMy���ǵ�V���X�?�	w�k����D���3 ��>Bw�(��t����޹�P_���k5t�Z�_����j��k5�1?��0���a3�z�c�F4��lh�ŗ����9O@s,���X�ͱ�)��	�f�%cZ���{x�p��ܸ�g 7����=�ݸ�ù�p�v��xn�jy7��⬳�-��b�q/�?��X,Y�*��I�'$'I��#���;�|������y�
9O,�E��Id1ݵ�$���l�XF�Ŧ��	�}Ni�tPU	z�f5'��5{$c�8 ��H�-��r����W�OD��	Fnô�X)�7�D'b�ј�fu�4�{i�1�+��^�tF5D�F4R�F4`�F4n�}R���������u��0�t�/g���Pױ;�c>�L&ݧs�Իg	{L�z驫����9cۙ���{��Ӷ$��^��T�uo�h�F�\[�{myD��uw�O2MV	�G�zf��g�N�I��vƢM��v�6�u���\�IJ��X�S�R'E����{�v��n��H�g�����D�?��y"˲�ΤkE�t�Y�����.?�*i��W�������*��S}q���֝O�>baL���7+F]���ӭ� ֪�TC��,+2����o|�w�^�"8~!:�K��C6	&��$"�L3�8$�C5��e.X����?t�q"⌭�y�A�[2.>��C�i޿X��BTN�@+]6L7�?��=��	�����M��?�TWK�ầ	\�AkSN�~	N���~���N#�����3��t��v/�OD"Yl"�,�d#X ɆPD�U�R������Q�/��h�%9��Gd��0*Mh�4�JF���O�`��)��?��ÈR����H�����i��i��i��?x|��I0�SBR�\	I7��_�E"�U��Ҝv���zA��C�Hu�:"L�s����9Y���_WDY	Atmm7�h��k������p1�/E��rNvYY/���2�������m��̼�r{����,
������|\��R'���fUt�L1��]�eɓ�����a�]�\�>���N��g[�Y��Ɋ�µ�6�V��O����*ޥ﫻P;�|�.��y��/�S0�d���+;������1AS��}z�}�D���lD~ݾré�K]72q�S��r��o\U��}[�;�uܱ#Z ;�U$���B���:6������VpF�E+(��VP�%ZA�K�����;���v����rT �䨐�vT�@;*D�&`8G��8G��.�
).�
)hG���B�Q!���vT���*�䨐�vT�@;*D�U���ʻ8*��8*��"Ў
hG���B�Q!�@��Q!���vT�@;j�����By��ByG�G���B�Q!���vT�@;*D��;9*��"Ў
hG�7;8*��9*�wqTHqqTHA;*D�"Ў
hG���B�Q����B
�Q!���d����1�>���������L���_�.���QE����"L�x�j_�z�$�G�З�-���\�H����i�>ezǏ.�w!�=S ���TFM&_�Eި��˒ �5E߲$�GMAW�e�P����pS�)	�-�MѺ$��)F��7E� �x\i9N����d�%©��d�PWE8���VivB[��	m�h'��i��kG�5lG���V��j'`U	N�wUC���!�M�00bU	XU�g;�I� �j�rV5D��NeXUCVՐ�Uu�	يqW5D9���T�;��!�jH���T0(gUC���A��V5$`U	XUC����]��j�jR���RQ5J�%q\V�M�%A\p.	:TK%i�j�Dp����
�㪥��섶ڳڪ�N@�ӊ�+֎Bk؎rS5�Z�S����	XU�%��q�R��q�R��qՒ]ոj�Nոj�N����NpR5�ZjT5�ZjT5�Z��W-թW-թW-թ��lŸ�W-5�W-�U����T����T����T������UK���UK���UKvU㪥:U㪥:U㪥:U�%��q�R��q�R��-���se&���Ƀ��5W��.�0�� 57��7�v�$%�z�%��f�as�P�����3��'��Ivd�:�m����Wp*7�[xI�7g)>�q݊�G�j����ۋf�K��{w�Xc�~����d:͏2k=q�����m��m�T�kn�W�mTW�z>��/T*禷"�����h�3ڦ#���]�.��E�$b�� �W8c���lS��"g@j���:~�]��W�Y�gpu:��X�֦+�K��4�Y=M!A�뜰["mh�Vy��|[i�3�X-˴HcY��U��خ���&��1�6WW���[4��n�7W�ӽjgzX�k2��@�Pdh5���qAY@ᘯlsc�n��b�)��6�Ku0�|��2'��uo�7��޷�7�-�6
�=�S�x{�3�4�Y���y�^XM�����̣\��XY泉4yO�,G��SE�X~�X���B9���?�_w��?�?Tj�OtFkU;��l��|��5wRi[�p�����46�݉�5*v5�gC4^O���m�蔖m㠻���l������R�ڵ�|@156oK{�1������]�cr�e����h�VA�W�*�M*�B'���	�kc�F��i��f�Gj:8������Ω��+(�o7߶6����:F��
�9#Ǚ'Lэy��|�::�$5ϼ �����4�r���g���������͸��V���.�6c8�[��LyZ��(�lv4$�#S���v�2M�o�9j��c�7�|&��Kc�&ߒ���'�ǙjM�\�T]�}g
��1:5�r���U�^#�;`�f�꬝'�^(Ү��c��:_�s�T̊�k�I��&�5�m_����d�KnM��	^�2��	�??u�>�&�s*�K��  �� PK     ! [m��	  �     word/webSettings.xml���J1��;,���Y�-�T���>@�ζ�L&̤���k�H/��I23���;��X�֌��� yZ��j���|pm*).-]��ق����l�7=,���)�*I��Y��ků�)C�ǎ]ђW�n��fW�"�P�v\�Wf��)
u]�pK~��ʮ�2D)�:d���S��x���=t!�����3	ue���'�Q�>�w'�������@�ܯ�[D�@'�3S̀r	>`N|�����v1R��p�����  �� PK     ! ^��my  �   docProps/core.xml �(�                                                                                                                                                                                                                                                                 ��Mo�0�����KZ��J���Ӑ&�}h�,1��&Qb(��/miY5�r���o�7Ig�"�`��jJ�ADP\��S򲜇8dJ�\+��#82ˮ�Rn�-x%�n�d�hJ�@����W�}j��0�ek��(�� �C�)�������ټ�B(t4���"��]l�+��B���E�-v���,�rP�j������s}�P��+$KOPbYJϡ����86�]�cn���٫�9 B�0l;�j�-W�o�Xj+��eต�s6G�6��+	��x�T�ha/�_��j�Kӓ�̈́ oU��V�F��9ɆQ�q���&FI}TC��ς�i�*N�z��@�S��f?   �� PK-      ! �H��  j	                   [Content_Types].xmlPK-      ! ���   N               �  _rels/.relsPK-      ! �G�N  u                 word/_rels/document.xml.relsPK-      ! �wF{C  �^              �	  word/document.xmlPK-      ! �#�e�  �               �L  word/footnotes.xmlPK-      ! �&��   !               �N  word/_rels/header2.xml.relsPK-      ! �cP�  �               �O  word/header1.xmlPK-      ! ��K�i  8
               �Q  word/header2.xmlPK-      ! :����  �               TU  word/endnotes.xmlPK- 
       ! z���r�  r�               cW  word/media/image1.pngPK-      ! �R%�#  �               �  word/theme/theme1.xmlPK-      ! �T0�  �               ^�  word/settings.xmlPK-      ! !���f  �               j�  customXml/itemProps2.xmlPK-      ! Lr_�                 .�  customXml/item2.xmlPK-      ! cR���   O               k�  customXml/itemProps1.xmlPK-      ! t?9z�   (               ��  customXml/_rels/item1.xml.relsPK-      ! \�'"�   (               ��  customXml/_rels/item2.xml.relsPK-      ! {���   (               ��  customXml/_rels/item3.xml.relsPK-      ! ���   (               �  customXml/_rels/item4.xml.relsPK-      ! �@(��  �               � docProps/app.xmlPK-      ! ��b#�   �                � customXml/item1.xmlPK-      ! _I -  =               � word/fontTable.xmlPK-      ! �C��   "               6	 customXml/item3.xmlPK-      ! ���	]  @               O
 customXml/itemProps3.xmlPK-      ! 5eX�   �                
 customXml/item4.xmlPK-      ! ����   U                customXml/itemProps4.xmlPK-      ! 0"���  U�               F word/styles.xmlPK-      ! [m��	  �               O word/webSettings.xmlPK-      ! ^��my  �               � docProps/core.xmlPK      �  :    



Adenocard - FDA prescribing information, side effects and uses



































Skip to Content












Search:



All

AllConsumerProfessionalPill IDInteractionsNewsFDA AlertsApprovalsPipelineClinical TrialsCare NotesEncyclopediaDictionaryNatural Products 










Browse all medications:

a
b
c
d
e
f
g
h
i
j
k
l
m
n
o
p
q
r
s
t
u
v
w
x
y
z


Advanced Search






Topics & Tools





Facebook 
Twitter 
Google Plus 






Sign In


Sign In
Register







Menu












 



Home › Professionals › FDA PI › Adenocard



Print
 Share






Adenocard
Generic Name: adenosine
Dosage Form: injection


Overview
Side Effects
Dosage
Interactions
Professional
Pregnancy

More

User Reviews
Support Group Q & A
Pricing & Coupons



Adenocard®  IV
(adenosine injection)
FOR RAPID BOLUS INTRAVENOUS USE








Description
Adenosine is an endogenous nucleoside occurring in all cells of the body. It is chemically 6-amino-9-β-D-ribofuranosyl-9-H-purine and has the following structural formula:

C10H13N5O4        267.24








Slideshow

	  		Looking Ahead: New Drug Approvals for 2017




Adenosine is a white crystalline powder. It is soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH. Adenosine is not chemically related to other antiarrhythmic drugs. Adenocard®  (adenosine injection) is a sterile, nonpyrogenic solution for rapid bolus intravenous injection. Each mL contains 3 mg adenosine and 9 mg sodium chloride in Water for Injection. The pH of the solution is between 4.5 and 7.5.
The Ansyr®  plastic syringe is molded from a specially formulated polypropylene. Water permeates from inside the container at an extremely slow rate which will have an insignificant effect on solution concentration over the expected shelf life.
Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

Clinical Pharmacology

Mechanism of Action
Adenocard (adenosine injection) slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
Adenocard is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenocard is not blocked by atropine.

Hemodynamics
The intravenous bolus dose of 6 or 12 mg Adenocard (adenosine injection) usually has no systemic hemodynamic effects. When larger doses are given by infusion, adenosine decreases blood pressure by decreasing peripheral resistance.

Pharmacokinetics
Intravenously administered adenosine is rapidly cleared from the circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells. This process involves a specific transmembrane nucleoside carrier system that is reversible, nonconcentrative, and bidirectionally symmetrical. Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Since adenosine kinase has a lower Km and Vmax than adenosine deaminase, deamination plays a significant role only when cytosolic adenosine saturates the phosphorylation pathway. Inosine formed by deamination of adenosine can leave the cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid. Adenosine monophosphate formed by phosphorylation of adenosine is incorporated into the high-energy phosphate pool. While extracellular adenosine is primarily cleared by cellular uptake with a half-life of less than 10 seconds in whole blood, excessive amounts may be deaminated by an ecto-form of adenosine deaminase. As Adenocard requires no hepatic or renal function for its activation or inactivation, hepatic and renal failure would not be expected to alter its effectiveness or tolerability.

Clinical Trial Results
In controlled studies in the United States, bolus doses of 3, 6, 9, and 12 mg were studied. A cumulative 60% of patients with paroxysmal supraventricular tachycardia had converted to normal sinus rhythm within one minute after an intravenous bolus dose of 6 mg Adenocard (some converted on 3 mg and failures were given 6 mg), and a cumulative 92% converted after a bolus dose of 12 mg. Seven to sixteen percent of patients converted after 1-4 placebo bolus injections. Similar responses were seen in a variety of patient subsets, including those using or not using digoxin, those with Wolff-Parkinson-White Syndrome, males, females, blacks, Caucasians, and Hispanics.
Adenosine is not effective in converting rhythms other than PSVT, such as atrial flutter, atrial fibrillation, or ventricular tachycardia, to normal sinus rhythm.


Indications and Usage
Intravenous Adenocard (adenosine injection) is indicated for the following.
Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to Adenocard administration.
It is important to be sure the Adenocard solution actually reaches the systemic circulation (see Dosage and Administration).
Adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following Adenocard administration.

Contraindications
Intravenous Adenocard (adenosine injection) is contraindicated in:

Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker).
Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
Known hypersensitivity to adenosine.






Warnings

Heart Block
Adenocard (adenosine injection) exerts its effect by decreasing conduction through the A-V node and may produce a short lasting first-, second- or third-degree heart block. Appropriate therapy should be instituted as needed. Patients who develop high-level block on one dose of Adenocard should not be given additional doses. Because of the very short half-life of adenosine, these effects are generally self-limiting. Appropriate resuscitative measures should be available.
Transient or prolonged episodes of asystole have been reported with fatal outcomes in some cases. Rarely, ventricular fibrillation has been reported following Adenocard administration, including both resuscitated and fatal events. In most instances, these cases were associated with the concomitant use of digoxin and, less frequently with digoxin and verapamil. Although no causal relationship or drug-drug interaction has been established, Adenocard should be used with caution in patients receiving digoxin or digoxin and verapamil in combination.

Arrhythmias at Time of Conversion
At the time of conversion to normal sinus rhythm, a variety of new rhythms may appear on the electrocardiogram. They generally last only a few seconds without intervention, and may take the form of premature ventricular contractions, atrial premature contractions, atrial fibrillation, sinus bradycardia, sinus tachycardia, skipped beats, and varying degrees of A-V nodal block. Such findings were seen in 55% of patients.

Bronchoconstriction
Adenocard (adenosine injection) is a respiratory stimulant (probably through activation of carotid body chemoreceptors) and intravenous administration in man has been shown to increase minute ventilation (Ve) and reduce arterial PCO2 causing respiratory alkalosis.
Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These effects have not been observed in normal subjects. Adenocard has been administered to a limited number of patients with asthma and mild to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenocard should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis, etc.) and should be avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenocard should be discontinued in any patient who develops severe respiratory difficulties.

Precautions

Drug Interactions
Intravenous Adenocard (adenosine injection) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile. Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard (see Warnings). Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents. The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation (see Warnings).
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline. In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective. Adenosine effects are potentiated by dipyridamole. Thus, smaller doses of adenosine may be effective in the presence of dipyridamole. Carbamazepine has been reported to increase the degree of heart block produced by other agents. As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies in animals have not been performed to evaluate the carcinogenic potential of Adenocard (adenosine injection). Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay.
Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations. Fertility studies in animals have not been conducted with adenosine.

Pregnancy Category C
Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. As adenosine is a naturally occurring material, widely dispersed throughout the body, no fetal effects would be anticipated. However, since it is not known whether Adenocard can cause fetal harm when administered to pregnant women, Adenocard should be used during pregnancy only if clearly needed.

Pediatric Use
No controlled studies have been conducted in pediatric patients to establish the safety and efficacy of Adenocard for the conversion of paroxysmal supraventricular tachycardia (PSVT). However, intravenous adenosine has been used for the treatment of PSVT in neonates, infants, children and adolescents (see Dosage and Administration).

Geriatric Use
Clinical studies of Adenocard did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, Adenocard in geriatric patients should be used with caution since this population may have a diminished cardiac function, nodal dysfunction, concomitant diseases or drug therapy that may alter hemodynamic function and produce severe bradycardia or AV block.

Adverse Reactions
The following reactions were reported with intravenous Adenocard (adenosine injection) used in controlled U.S. clinical trials. The placebo group had less than 1% rate of all of these reactions.

Cardiovascular
Facial flushing (18%), headache (2%), sweating, palpitations, chest pain, hypotension (less than 1%).

Respiratory
Shortness of breath/dyspnea (12%), chest pressure (7%), hyperventilation, head pressure (less than 1%).

Central Nervous System
Lightheadedness (2%), dizziness, tingling in arms, numbness (1%), apprehension, blurred vision, burning sensation, heaviness in arms, neck and back pain (less than 1%).

Gastrointestinal
Nausea (3%), metallic taste, tightness in throat, pressure in groin (less than 1%).

Post Marketing Experience (see Warnings)
The following adverse events have been reported from marketing experience with Adenocard. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.

Cardiovascular
Prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood pressure, bradycardia, atrial fibrillation, and Torsade de Pointes

Respiratory
Bronchospasm

Central Nervous System
Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness.



Overdosage
The half-life of Adenocard (adenosine injection) is less than 10 seconds. Thus, adverse effects are generally rapidly self-limiting. Treatment of any prolonged adverse effects should be individualized and be directed toward the specific effect. Methylxanthines, such as caffeine and theophylline, are competitive antagonists of adenosine.

Dosage and Administration
For rapid bolus intravenous use only.
Adenocard (adenosine injection) should be given as a rapid bolus by the peripheral intravenous route. To be certain the solution reaches the systemic circulation, it should be administered either directly into a vein or, if given into an IV line, it should be given as close to the patient as possible and followed by a rapid saline flush.

Adult Patients
The dose recommendation is based on clinical studies with peripheral venous bolus dosing. Central venous (CVP or other) administration of Adenocard has not been systematically studied.
The recommended intravenous doses for adults are as follows:
Initial dose: 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period).
Repeat administration: If the first dose does not result in elimination of the supraventricular tachycardia within 1-2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a second time if required.

Pediatric Patients
The dosages used in neonates, infants, children and adolescents were equivalent to those administered to adults on a weight basis.
Pediatric Patients with a Body Weight < 50 kg:
Initial dose: Give 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally. A saline flush should follow.
Repeat administration: If conversion of PSVT does not occur within 1-2 minutes, additional bolus injections of adenosine can be administered at incrementally higher doses, increasing the amount given by 0.05 to 0.1 mg/kg. Follow each bolus with a saline flush. This process should continue until sinus rhythm is established or a maximum single dose of 0.3 mg/kg is used.
Pediatric Patients with a Body Weight ≥ 50 kg: Administer the adult dose.
 
Doses greater than 12 mg are not recommended for adult and pediatric patients.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

How Supplied
Adenocard®  (adenosine injection) is supplied as a sterile non-pyrogenic solution in normal saline.
NDC 0469-8234-12 Product Code 823412
6 mg/2 mL (3 mg/mL) in 2 mL (fill volume) Ansyr®  plastic disposable syringe, in a package of ten.
NDC 0469-8234-14 Product Code 823414
12 mg/4 mL (3 mg/mL) in 4 mL (fill volume) Ansyr®  plastic disposable syringe, in a package of ten.
Store at controlled room temperature 15º-30ºC (59º-86ºF).
DO NOT REFRIGERATE as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. The solution must be clear at the time of use.
Contains no preservatives. Discard unused portion.
May require needle or blunt. To prevent needle-stick injuries, needles should not be recapped, purposely bent or broken by hand.
Rx Only

REFERENCE
1. Paul T, Pfammatter. J-P. Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatric Cardiology 1997; 18:118-126.
Ansyr®  is a registered trademark of Hospira, Inc.
Product of Germany
 
 Marketed by:
Astellas Pharma US, Inc.
Northbrook, IL 60062 USA
 
Manufactured by:
Hospira, Inc.
Lake Forest, IL 60045 USA
Revised: May 2012
12D026-ADC-SPL

Principal Display Panel

2 mL Syringe Carton


Principal Display Panel

4 mL Syringe Carton





Adenocard 
adenosine solution





Product Information


Product Type
HUMAN PRESCRIPTION DRUG LABEL
Item Code (Source)
NDC:0469-8234


Route of Administration
INTRAVENOUS
DEA Schedule
    








Active Ingredient/Active Moiety


Ingredient Name
Basis of Strength
Strength


ADENOSINE (adenosine)
ADENOSINE
3 mg  in 1 mL











Packaging


#
Item Code
Package Description


1
NDC:0469-8234-12
10 SYRINGE, PLASTIC in 1 PACKAGE


1

2 mL in 1 SYRINGE, PLASTIC


2
NDC:0469-8234-14
10 SYRINGE, PLASTIC in 1 PACKAGE


2

4 mL in 1 SYRINGE, PLASTIC











Marketing Information


Marketing Category
Application Number or Monograph Citation
Marketing Start Date
Marketing End Date


NDA
NDA019937
10/30/1989









Labeler - Astellas Pharma US, Inc. (605764828)



Revised: 05/2012


 
Astellas Pharma US, Inc.
Next → Pregnancy Warnings

Share on GooglePlus
Share on Facebook
Share on Twitter
Print this page
Email to a friend
 Add to My Med List


More about Adenocard (adenosine)

Side Effects
During Pregnancy
Dosage Information
Drug Interactions
Support Group
Pricing & Coupons
0 Reviews – 
Add your own review/rating
Generic Availability
Drug class: cardiac stressing agents

Consumer resources

Adenocard
Adenocard (Advanced Reading)

Professional resources

Adenosine (AHFS Monograph)
Adenosine (FDA)

Other brands: Adenoscan
Related treatment guides

Radionuclide Myocardial Perfusion Study
Supraventricular Tachycardia
Wolff-Parkinson-White Syndrome








FEATURED: CAR-T Cell Therapy



→ Overview
→ Mechanism of Action
→ KTE-C19 Studies
→ KTE-C19 Cancer Targets
→ Adverse Events
→ Manufacturing





Drug Status



Availability Rx Prescription only



Pregnancy Category C Risk cannot be ruled out




CSA Schedule N Not a controlled drug




Approval History Calendar Drug history at FDA





Close











Drug Class


Cardiac stressing agents
Group V antiarrhythmics



Related Drugs


cardiac stressing agents dipyridamole, adenosine, dobutamine, Persantine, Lexiscan, regadenosongroup V antiarrhythmics digoxin, Lanoxin, adenosine, Digitek, AdenoscanSupraventricular Tachycardia metoprolol, atenolol, diltiazem, amiodarone, verapamil, Toprol-XL, Cardizem, More...Wolff-Parkinson-White Syndrome flecainide, propafenone, adenosine, Rythmol, Tambocor, Adenoscan, More...Radionuclide Myocardial Perfusion Study dipyridamole, adenosine, Persantine, Lexiscan, regadenoson, Adenoscan, More... 




FDA Consumer Updates



Depression: FDA-Approved Medications May Help
Dealing with ADHD: What You Need to Know
Making Decisions for Your Health: Getting the Info You Need
FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance

More FDA updates




Adenocard Rating



              No Reviews - Be the first!









      No Reviews - Be the first!


      Not Rated - Be the first!




Related News and Articles




Heart Devices 101: Guide to the Tools That Keep You Ticking
April 2, 2017


No Link Between Caffeine, Irregular Heartbeat in Heart Failure Patient Study
October 17, 2016


Smartphone Device Detects Undiagnosed Irregular Heartbeat
October 13, 2016











Drugs.com Mobile Apps
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.
Explore Apps











Support

Help Center
Frequent Questions
Sitemap
Contact Us



About

About Drugs.com
Advertising Policy
Content Submissions
Drugs.com Blog



Terms & Privacy

Editorial Policy
Privacy Policy

Terms of Use
Attribution & Citations





Facebook 
Twitter 
Google Plus 
YouTube 
RSS Feed 


Subscribe to receive email notifications whenever new articles are published.




Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated July 5th, 2017), Cerner Multum™ (updated July 13th, 2017), Wolters Kluwer™ (updated July 5th, 2017) and  others. To view content sources and attributions, please refer to our editorial policy.








Third Party Advertising


We comply with the HONcode standard for trustworthy health information - verify here


Copyright © 2000-2017 Drugs.com. All rights reserved.









Share on Facebook
Share on Twitter
Share on GooglePlus
Email to a friend

Hide



























	ADRENACARD Trademark of Intelliject, Inc.. Serial Number: 77693403 :: Trademarkia Trademarks





























































Apply Online!
Attorneys

Services 

U.S. Trademark Registration Service 
International Trademark Registration Service 
Trademark Office Action Response 
Trademark Statement of Use 
Trademark Renewal 
Trademark Assignment 
Trademark Watch 
Trademark Cease & Desist  
Trademark Comprehensive Search  
Copyright Registration 
Patent Services 
Incorporation Services 
Business Page Creation 
 More Services... 


Help
Contact Us


Login






















Trademark Search 
Trademark Category
Medical Instrument Products
ADRENACARD










 
Get FREE email alerts













ADRENACARD  Trademark Information
 Intelliject, Inc.
drug delivery systems




Perfect for these industries

Medical Instrument Products





Words that describe this mark
drug   delivery   systems    
                                    




This is a brand page for the ADRENACARD trademark by Intelliject, Inc. 
                                in Richmond, VA, 23219.
Write a review about a product or service associated with this ADRENACARD trademark.    
                                Or, contact the owner Intelliject, Inc. of the ADRENACARD trademark by filing a request to communicate with    
                                the Legal Correspondent for licensing, use, and/or questions related to the ADRENACARD trademark.
                           






On Wednesday, March 18, 2009,  a U.S. federal trademark registration was filed for 
                        ADRENACARD by 
                        Intelliject, Inc., Richmond, VA  23219.
                        The USPTO has given the ADRENACARD 
                        trademark serial  number of  77693403.  
                        The current federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED.
                        The correspondent listed for ADRENACARD is 
                        
                        
                                            SUSAN L. PIASCIK of 
                                            COOLEY LLP,  777 6TH ST NW STE 1100, WASHINGTON, DC 20001-3706 
                                .
                            The ADRENACARD trademark is filed in the category of 
                            
                                    Medical Instrument Products
                                . 
                            The description provided to the USPTO for ADRENACARD 
                            is drug delivery systems. 
                            





Word mark:
 ADRENACARD


  Status/Status Date:  


ABANDONED - NO STATEMENT OF USE FILED

11/12/2012






  Serial Number:  
77693403


  Filing Date:  
3/18/2009


 Registration Number:  
NOT AVAILABLE


 Registration Date:  
NOT AVAILABLE


 Goods and Services: 
drug delivery systems


 Mark Description: 
NOT AVAILABLE


 Type Of Mark: 
TradeMark


 Published For Opposition Date: 
7/21/2009


Last Applicant/Owner:

Intelliject, Inc.Richmond, VA  23219
Why is this contact information displayed?  

Why is this contact information displayed? [Close]
The USPTO makes this data available for search by the public so that individuals can locate ownership information for intellectual property, much the same way a county might make real estate property ownership information available.
Since our website is synchronized with the USPTO data, we recommend making any data changes with the USPTO directly. Our website will auto-update when the USPTO data is updated.
You may also contact Trademarkia to make a request for the removal of your personally identifiable information or trademark data.  Such requests must be made in writing and will be subject to verification of ownership.  This policy allows verified trademark owners to specify: (A) that their identifiable information be masked, or (B) that their trademark pages permanently deleted from Trademarkia.com.  
                                                Requests may be made directly to customer.service@trademarkia.com and every effort will be made to honor them within 48 hours. 
Click here for further details.
[Close]




 Mark Drawing Code:  
Standard Character Mark


 Design Search: 


(NO DATA)



Register Type:  
Principal


 Disclaimer:
 (NOT AVAILABLE)


 Correspondent:


SUSAN L. PIASCIK
COOLEY LLP
777 6TH ST NW STE 1100
WASHINGTON, DC 20001-3706






 Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.





Classification Information



Primary Class: 
 Class (010) - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.


First Use Anywhere: 
Not provided


First Use In Commerce: 
Not provided





Trademarkia is the largest search engine for U.S. trademarks.  Each month hundreds of trademarks around the world are filed by licensed attorneys in the LegalForce/Trademarkia network! You can register your trademark in 170+ countries in the world through LegalForce Network.
 LegalForce Network can help you incorporate a business around your ADRENACARD trademark in less than 5 minutes.  Trademarkia makes the process easy and convenient, so start now!
 Trademarkia.com is a free search engine of publicly available government records.  Trademarkia.com is not a law firm and does not represent owners & correspondents listed on this page.
Trademark Document Retrieval >>







Trademark - Apply Online!


100% Satisfaction Guarantee protect your valuable brand now.



How it works?
What you get?






1. Legalforce RAPC - #1 U.S. Trademark Filing from 2010 to now.
2. Describe how your business or product is being used. Register your mark in 176+ countries. Just $199 + govt fees! Start here >>






1. Top Global IP Attorneys - Credibility and Experience!
2. All processes will be performed in a timely manner. You will be informed periodically about the process.






Keep Track of this Brand.

 Trademark Watch Services
Keep track of how your trademark is being used. Available in the United States and in more than 176 countries. Round-the-clock monitoring. Monthly report on potential infringement.
                                

Watch this Trademark 

Trademark Watch Services read more...

Current Trademark Status:

11/12/2012
ABANDONED - NO STATEMENT OF USE FILED


Free Trademark Search:






Correspondent Search:



SUSAN L. PIASCIK


                                             
                                         is a correspondent of ADRENACARD trademark. 
                            	    


Current Overall Rating:

 (0 review)
                            
What You Can Do:




Start Your Business



FREE Logo Creator



Add to Favorites



View Documents



FREE Trademark Search



Start Trademark Filing Process



Protect this Mark Internationally



Custom Logo Design $159



Search adrenacard on popular social networks






                                Trademarkia lets you see how your 
                                personal name, product name, 
                                trademark name or username is being used on any of 530+ new 
                                and popular social networks.  
                                Be the first to reserve your name  and get help stopping others from using it - all in one place!















Trademark Oppose Service


You can request for Extension of Time to Oppose this mark or Oppose it now.



                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password;
                 

                 - If you already have a LegalForce/Trademarkia account, please enter your account's email and password.
                


* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



* 



 Please enter the value




 

  
                             



 







Status Update Alerts

Status Update Alerts are email updates of the latest trademark status change. Please make sure you provide the correct email. 


                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password;
                 

                 - If you already have a LegalForce/Trademarkia account, please enter your account's email and password.
                


* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



* 



 Please enter the value




 

  
                             



 









Review & Rating

Please Rate and Review for ADRENACARD 




ADRENACARD is providing drug delivery systems.
                


                 - If you are new to LegalForce/Trademarkia, please just enter your contact email and create a password to be associated with your review.
                 

                 If you already have a LegalForce/Trademarkia account, please enter your account's email and password before posting your review.
                 


* Please Rate: 


     




* Your Review: 



 Please enter your review.



* Email Address: 


 Please enter your email address



* Enter Password: 


 Please enter your password



 

  
                             



 


























Consulting Projects : University Economic Development : OVPR : University of Minnesota





















Main navigation | 
    Main content




Campuses: 

Twin Cities
Crookston
Duluth
Morris
Rochester
Other Locations





Go to the U of M home page


OneStop myU


Search U of M Web sites

















Home
Research
Business
News
About

















Home

About
Contact
Research
Recruitment
Workforce & Immigrants
Training
Fellows Program
Consulting Projects
Resources


Front Door Request








Consulting projects
Learn more about our Economic Development Fellows Consulting Program projects and clients.

Companies are invited to submit a project proposal or contact frontdoor@umn.edu for more information.
Summer 2017 projects
Students can apply for a summer 2017 project starting at 6 p.m. Mon., May 22. The application closes at midnight on Mon., May 29.
Company: Activated Research Company
Industry: Material science analytics
Project type: Market research and analysis
Project lead: Jake Petersburg
This project is focused on developing new customers and markets for the Polyarc reactor, an instrument used to detect, identify and measure molecules. These may include pharmaceutical, military, or other markets that have, as yet, seen little adoption of this technology. Deliverables may include a written analysis of these markets including potential for the reactor and suggested strategies for market penetration. This may also include suggestions for grant applications (e.g., SBIR) that could be used to develop specialized versions of the Polyarc for these markets.
Company: Doubting Thomas Farms
Industry: Organic agriculture
Project type: Business development
Project lead: Mike Wilson, wils0888@umn.edu
This project is with a family owned farm that is moving into new products like value added organic granola, oats, and humane eggs, poultry and beef for restaurants and schools. The project will focus on recommendations for information and data collection around these products, market expansion, revenue generation options, economic impact assessment, and others.
Company: iMediplus Inc. (through Interyl Consulting)
Industry: Medical devices
Project type: Product improvement/Market research and analysis
Project lead:  Zahra Masoud, masou007@umn.edu
The project includes both a technical/medical demonstration of a "smart" stethoscope as well as investigating possible business model options. The key deliverables would include: 1) Connecting with medical professionals to gather feedback on the "smart" stethoscope in a medical setting 2) Developing and comparing at least three potential business models with a recommended best model 3) Recommendations on next steps to further refine technical/medical and business areas for a U.S. product launch in 2018.
Company:  Intent Health, Inc.
Industry: Medical devices (startup)
Project type: Business development/market research
Project lead: Wilson Yu, wjyu@umn.edu
This startup company is developing a new, wearable neurodiagnostic system with wireless earbuds that sense EEG, ECG, PulseOx, temperature, posture, movement and speech. The company is looking for review of its pitch deck and business plan for gaps and hoping to develop a venture capital-ready investor package, including a market analysis. On this project the team will also make recommendations on the best market to enter first.
Company: Lake Superior Consulting (LSC) 
Industry: Energy infrastructure
Project type: Market research and analysis
Project lead: Suyue Chen, chen3094@umn.edu
LSC is a Duluth based company that provides engineering expertise to the energy sector.  There are many opportunities for business growth in the energy sector by solving issues facing the industry such as corrosion in refineries and pipelines, geology of drilling operations, and  infrastructure failure prevention and detection. On this project the team will explore some of these issues and recommend solutions that will help the company grow existing business and enter new markets.

Spring 2017 projects
Company: ISurTec
Industry: Surface technologies/medical devices
Project type: Business development
Project lead: Zahra Masoud, masou007@umn.edu
ISurTec is a small business that develops and manufactures coatings for medical devices. It is currently working on a Phase II SBIR (Small Business Innovation Research) grant to develop a coating that can improve the product life of ureteral stents by preventing encrustation. The EDF consulting team will support the creation of the commercialization section of the SBIR, specifically the content regarding the marketing, regulatory, IP (intellectual property) and financial projections for the new ureteral stent coating.
Company: Kerry
Industry: Food and nutrition
Project type: Market research
Project lead: Shawna Persaud, pers0126@umn.edu
Kerry makes high quality food products that meet vital nutritional needs for people in all parts of the world. Wellmune is the company’s proprietary, award-winning ingredient, demonstrated to support human immune health. The company is currently developing Wellmune 2.0, a second generation immune health ingredient that could include probiotics, prebiotics, microbial-associated molecular patterns and other immune-related components. The EDF consulting team will assist in the scientific and market evaluation of Wellmune 2.0.
Company: Aucta Technologies, Inc.
Industry: Medical devices
Project type: Market research
Project lead: Wilson Yu, wjyu@umn.edu
Aucta Technologies, Inc. is an early stage startup developing a take-home device as a method for nerve stimulation. The technology has potential applications in several areas including obesity, diabetes and arthritis. The EDF consulting team will assess three to four potential applications for the nerve stimulation technology. The final report will highlight market size, competition and potential pathways to market from comparable devices.
Company: Cellnovo
Industry: Medical devices
Project type: Product improvement
Project lead: Jacob Petersburg, pete6386@umn.edu
The Cellnovo System is the world’s first mobile diabetes management system, including an insulin patch pump, activity monitor, cellular-enabled wireless touchscreen handset with integrated blood glucose meter and automatic connectivity to a secure server. The EDF consulting team will analyze data from patients to determine how effectively the insulin is delivered based on inputs of various patient parameters such as food intake, activity levels and entry of blood glucose levels.
Company: TTrost Collection
Industry: Health services
Project type: Business development
Project lead: Michael Wilson, wils0888@umn.edu
TTrost Collection is an art-based reminiscence program which transforms the tradition of reminiscing through exposure to fine art. For participants with dementia, the program provides opportunities for improved memory recall through sensory integration and exposure to the creative process through art and cooking activities that explore their feelings and foster identity. The EDF consulting team will help assess the current model of the TTrost Collection program and identify potential opportunities for improvement.
Return to top of page
Case studies
Winter 2016
AdrenaCard
Industry: Pharmaceuticals
Project type: Patent analysis
AdrenaCard is a Minneapolis-based pharmaceutical company that packages proven medication with delivery systems that are easier to carry, more intuitive to use, and more accessible to those who need them. The company partnered with the EDF Consulting Program to evaluate certain aspects of their first product development strategy as well as evaluate additional opportunities they could focus on in the future. The consulting team assessed competitive market forces and made recommendations for AdrenaCard's product development strategies.
Deliverables
• Investigate competitors’ product development strategies to further
inform AdrenaCard’s current plans
• Create high level assessment of market potential, competition, and economic contribution for targeted opportunities

• Final presentation and report created for AdrenaCard leadership team of the business case
Outcomes
• Identification and evaluation of three new markets to provide additional growth opportunities for the company
• In three years, seven jobs could be created for the company in addition to paid consultant work offered to two EDF team members

• Substantial reduction in labor and legal fees
Birchwood Laboratories
Industry: Medical devices
Project type: Global business development
Birchwood Laboratories is a medical manufacturer in the Twin Cities that provides healthcare professionals and their patients with quality products for wound care and prevention, incontinence, and associated skin conditions. Birchwood Laboratories partnered with the EDF Consulting Program  to help examine international markets. International Life-Science Enterprises (ISLE) was contracted to manage the program with EDF on behalf of Birchwood Laboratories. The goal of this project was to determine the most profitable and rapid strategies and associated tactics to optimize the potential of their product line in the foreign marketplace. The EDF consulting team evaluated the new market entry strategy for ISLE/Birchwood over the course of 12 weeks. 
Deliverables
• Stratify the available international market, identify key competitors and determine any barriers to entry for Birchwood products
• Develop the marketing, sales, regulatory and distribution strategies required to introduce Birchwood products internationally


• Evaluate ecommerce potential and how to initiate sales
Outcomes
• Birchwood is moving to establish distribution into the Asian market with Japan as the initial objective
• Birchwood will contract one employee to spearhead expansion into ecommerce starting with Amazon as well as social media
• Market analysis and entry strategy deliverables valued at $15,000 to $20,000


Collagen Solutions
Industry: Biotechnology, medical devices
Project type: Market & competitive analysis
Collagen Solutions is a global biotechnology/medical device company that develops, manufactures, and supplies medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine. Collagen Solutions is developing a medical grade collagen film, but the potential applications for the device are undefined. In winter 2016, the EDF Consulting Program team conducted market research to determine the market fit, market size, regulatory barriers, and competitive landscape in five different potential indications for the medical grade collagen film.
Deliverables
• High-level analysis of market fit for five different potential applications for the medical grade collagen film, corresponding to 11, new markets
• Detailed analysis of competition, regulatory barriers, key research and development needs, and market size

• Recommendations for which new markets are most promising for Collagen Solutions
Outcomes
• Identified and analyzed six distinct markets based on the product market fit, market size, market growth, regulatory barriers, research and development requirements, and competition
• Successful entry into these new markets will provide Collagen Solutions with increased revenue and will create new jobs to support the development and sale of the film

• Mitigated risk and informed research and development and market-entry strategies
Ecolab
Industry: Food and beverage
Project type: Product development
Ecolab is the world leader in water, energy, and hygiene technologies and services. The EDF Consulting Program partnered with Ecolab’s food and beverage division in the field of rapid prototyping of digital solutions to provide Ecolab the information and resources to implement a rapid prototype so that it can react in a more efficient manner to customer needs.
Deliverables
• Provide market research on voice of the customer
• Identify current unmet customer need(s)

• Evaluate best practices in prioritization methods
Outcomes
• Ecolab is considering new ways to calculate impacts and communicate food safety risks to customers
• Ecolab is considering new ways to leverage existing IT investments for enhancement of voice of customer insights and socializing knowledge

LADi Water
Industry: Water purification technology
Project type: Market research
LADi Water is a startup water technology firm located in the Twin Cities that is developing technology in desalination. LADi Water is progressively aware of the current shortcomings in water purification and wants to introduce their innovative technology into the market. They partnered with the EDF Consulting Program to assess and characterize the market fit and potential for LADi Water’s device within the water purification market. The EDF team conducted market research to identify accessible vertical markets to enter, market leaders, and performed a comparative analysis between existing and upcoming water purification technologies and LADi Water’s system over the course of 12 weeks.
Deliverables
• Categorize the water purification market, locally and internationally, based on specialized needs of customers and identify key market leaders
• Create company profiles for market leaders including business analyses, geography, and existing technology offered


• Evaluate current technological trends and usage within the market, research for new surfacing technologies, and identify how LADi Water’s system compares
Outcomes
• Data collected will inform future decisions about defining initial primary market, including which regions are good candidates, understanding where existing technology falls short, and ensuring the market entered is receptive to the technology.

• Identified the technology’s key features and limits that will be implemented in the next round of prototyping in order for LADi Water to be viable competition in specific markets
• Market analysis and entry strategy deliverables valued from $3000 to $10,000

Summer 2016
International Life Science Enterprises (ISLE) 
Industry: Medical devices
Project type: Market entry strategy
In summer 2016, International Life Science Enterprises (ILSE), a Twin Cities’ consulting company, partnered with the Economic Development Fellows Consulting Program to address an international client’s need. A Japanese client had recently acquired a dental implant system technology and wanted to expand its product line to the North American market.The consulting team evaluated the new market entry strategy for ISLE’s client over the course of 12 weeks.
Deliverables
• Market and competitor analysis of the Canadian and United States dental implant marketplace
• Marketing and sales strategies to introduce the dental implant in Canada and the United States
• Project deliverables valued at $21,400
Outcomes
• ILSE is employing consulting team recommendations for market expansion of the dental implant to the more lucrative North American dental implant market
• Following the completion of the project, ILSE was contracted by their Japanese client for one year to execute a client project
• ILSE hired a member of the consulting team to help continue project execution.
Lite Run Inc.
Industry: Medical devices
Project type: Market analysis
Lite Run’s mission is to support the $20B U.S. rehabilitation industry with a novel medical device that helps people regain their ability to stand and walk following an injury or disability. Lite Run initially targeted the device for rehabilitation facilities in hospitals and skilled nursing facilities. However, the company is exploring other markets, including the use of their device in intensive care units, where there is a growing trend to get patients walking as soon as possible. The goal of the summer 2016 project was to help Lite Run assess the potential for its device in this market and create market entry recommendations.
Deliverables
• Market size and potential revenue
• Market fit for the product and consumer needs
• Competitive analysis of products currently in the space
• Preliminary market entry strategy including:
        - Product modification recommendations
        - Potential research partnerships
        - Analysis of business model options
• Project deliverables valued at $25,000
Outcomes
• Client gained a market entry strategy to a previously inaccessible market. Over the next two to three years, this has the potential to:
        - Boost company revenue
        - Create new jobs
        - Generate I.P.
        - Mitigate company risk by diversifying revenue sources
• Client also gained access to new investment opportunities due to the expanded market opportunities the project provided
Microbiologics
Industry: Biotechnology
Project type: Market analysis
Microbiologics offers the largest and most diverse line of ready-to-use quality control microorganisms, diagnostic products used to help healthcare professionals properly diagnose patient disease and treatment plans and to ensure that no contamination is present in food, water, medicine and cosmetics. In summer 2016, Microbiologics partnered with the Economic Development Fellows Consulting Program and Clear Path LLC, a consulting firm specializing in strategy implementation, to identify new opportunities to drive future growth and value creation.
Deliverables
• Client core competencies to identify new business opportunities in adjacent markets
• High level assessment of market potential, competition and economic contribution for targeted opportunities
• Final report on business case for targeted opportunities to Microbiologics leadership team
• Project deliverables valued at $25,000
Outcomes
• By implementing the recommendations, it is estimated that by 2020 Microbiologics will achieve a goal of driving continued strong growth (15-25 percent per year) by penetrating a new market
• In five years, up to 15 local jobs could be created for Microbiologics to address these new markets
• In 10 years, the revenues in this new market could represent  up to 20 percent of total Microbiologics revenues
Return to top of page






















    200 Oak St. SE, Suite 230 · Minneapolis, MN 55455 ·612-626-3438
    
Site Map
Contact Us






© 2016 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer
Last modified on May 22, 2017




Twin Cities Campus: 
Parking & Transportation
Maps & Directions

Directories
Contact U of M
Privacy

 

























 



 Mammography Equipment Market Pipeline 2016 and Companies Report 
         










    









 






 











 









Mammography Equipment Market Pipeline 2016 and Companies Report

Oct 05, 2016, 02:00 ET
		  		  															
						 from   RnR Market Research 











 
















































 

 




















 


PUNE, India, October 5, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Mammography Equipment - Medical Devices Pipeline Assessment, 2016" market research report to its store providing comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Mammography Equipment pipeline products.
Complete report on Mammography Equipment Market with 103 market data tables and 6 figures, spread across 135 pages is available at http://www.rnrmarketresearch.com/mammography-equipment-medical-devices-pipeline-assessment-2016-market-report.html .
This report is prepared using data sourced from in-house databases, secondary and primary research. Companies discussed in this Spinal Muscular Atrophy Pipeline Review, H2 2016 report include Actis Biologics, Inc, Advanced Research Technologies, Inc., Analogic Corporation, Canon U.S.A., Inc., CapeRay Medical (Pty) Ltd, FMI Technologies, Inc., FUJIFILM Medical Systems USA, Inc., Health Discovery Corporation, Imaging Diagnostic Systems, Inc., Mobile Electronic Diagnostics (MobED), NovaScan, LLC, PETsys Electronics SA, Philips Healthcare, Real Imaging Ltd, Real Time Tomography, LLC, Seno Medical Instruments, Inc., Tribogenics, Inc., University College London, University of Calgary, University of Manchester, University of Saskatchewan, University of South Florida, Varian Medical Systems, Inc., Weinberg Medical Physics, LLC, XLV Diagnostics Inc. and Z-Tech, Inc.
Scope of this research report: Extensive coverage of the Mammography Equipment under development. The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities. The report reviews the major players involved in the development of Mammography Equipment and list all their pipeline projects. The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage. The report provides key clinical trial data of ongoing trials specific to pipeline products and recent developments in the segment / industry.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=704281 .
The report enables readers to:-

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Mammography Equipment under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

Another newly published market research report titled on Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016 provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Injectable Drug Delivery pipeline products. Companies Involved in Therapeutics Development are Aciont Inc., Actavis Inc., AdrenaCard, Inc., Allergan, Inc., Alsensa ApS, AMAG Pharmaceuticals, Inc., Amgen Inc., Antares Pharma, Inc., Anterion Therapeutics, Inc., Arnali, LLC, Artemes Technologies, Inc., AstraZeneca Plc, Atanse, Inc., AzureBio, S.L., Becton, Dickinson and Company, Bespak Europe Ltd., Biodel Inc., BioMarin Pharmaceutical Inc., BioRestorative Therapies, Inc., Boston University, BTG Plc, Burke Pharmaceuticals, LLC, Callisyn Biomedical Inc, Cambridge Consultants Limited, Case Western Reserve University, Cincinnati Children's Hospital Medical Center etc. Injectable Drug Delivery market research report of 402 pages is available at http://www.rnrmarketresearch.com/injectable-drug-delivery-medical-devices-pipeline-assessment-2016-market-report.html .
Explore more reports on Medical Imaging.
About Us: 
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.
Contact:  
Ritesh Tiwari
2nd floor, Metropole,
Next to Inox theatre, Bund garden road,
Pune-411001
Maharashtra, India.
+ 1 888 391 5441
sales@rnrmarketresearch.com


 SOURCE  RnR Market Research  




  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  











Oct 05, 2016, 08:30 ET
Preview: Aeroderivative Gas Turbine Market: 4.59% CAGR to 2020













Oct 04, 2016, 06:00 ET
Preview: Electric Hoist Market Competitive Landscape Analysis for 2016-2021






My News


  Release contains wide tables.	  View fullscreen.





Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


 








Page not found - TheStreet

















 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street




































 
















Page not found

        Sorry, the page you're looking for is not available.
    
    You might want to try:
    

Our homepage


Our most popular stories






























 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 












